Electrochromic compounds and optical articles containing them

Abstract

To improve electrochromic materials so that they can be used as a transparent medium for forming high-quality articles, especially high-quality eyeglass lenses, while maintaining electrochromic properties and having a wide range of colors. [Solution] The present invention relates to a novel group of electrochromic compounds. More specifically, the present invention relates to benzazole and condensed azole compounds substituted with one or more pyridinium rings, and the use of these compounds as variable transmittance media for the manufacture of optical articles such as spectacle lenses.

Description

[Technical Field]

[0001] This invention relates to a novel group of electrochromic compounds. More specifically, it relates to benzazole and condensed azole compounds substituted with one or more pyridinium rings, and to the use of these compounds as variable transmittance media for manufacturing optical articles such as spectacle lenses. [Background technology]

[0002] Electrochromism is a well-known physical phenomenon observed in certain classes of compounds whose color reversibly changes when a voltage is applied. These materials exhibit reversible changes in optical properties through oxidation and reduction. Advantageously, electrochromic materials are colorless when no electric field is applied and develop color when an electric field is applied.

[0003] Electrochromic devices, i.e., devices containing electrochromic compounds whose absorbance depends solely on the presence of an electric field, can therefore have two states: a colored state (when electrically activated) and a bleached state (inactive). The light transmission properties of the device depend on the properties of the electrochromic compound. [Overview of the Initiative] [Problems that the invention aims to solve]

[0004] There is still a need to improve electrochromic materials to maintain their electrochromic properties and have a wide range of colors, so that they can be used as a transparent medium for forming high-quality articles, especially high-quality eyeglass lenses. [Means for solving the problem]

[0005] Surprisingly, the inventors discovered that introducing an azole or azolium ring into the structure of an electrochromic molecule reduces the absorption wavelength in the visible region. In fact, it was confirmed that various azole rings were introduced and efficiently broadened the wavelength range with various activation potentials. This included, for example, substituted imidazolium and condensed ring derivatives, substituted benzimidazolium, and substituted benz(iso)thiazolium compounds. In addition, the viologen molecule, or benzazole molecule, or condensed azole-containing molecule of the present invention exhibits a reduction potential of 1 or 2.

[0006] For example, viologen molecules are typically bication (bipm 2+ ) to monocation (bipm + ), from monocation to neutral species (bipm 0 It shows two reduction potentials to ). [ka]

[0007] bipm 2+ from bipm + The reaction to is a reversible reaction that occurs at the first potential E1, and bipm + from bipm 0 The reaction to bipm occurs at a lower potential E2 and is often irreversible. 0 It is an unstable compound and is thought to potentially react with oxygen or other molecules present in the device, changing its chemical structure and potentially losing its electrochromic properties.

[0008] Therefore, the inventors attempted to improve the device's stability and thus its lifespan by modifying the chemical structure and widening the distance between the two reduction peaks. The added chemical groups are such that the potential distance between these two reduction peaks is less than 0.1V, preferably less than 0.3V, and more preferably less than 0.5V.

[0009] As a result of diligent research, the present inventors have provided a novel electrochromic compound that exhibits excellent electrochromic properties and can be easily incorporated into cells to form, for example, electrochromic lenses. Thus, the compounds of the present invention are advantageous as follows: - In its inactive state, it is colorless, but in its activated state, it has a color such as green, red, purple, blue, yellow, or brown. - It is reversibly oxidized or reduced. - It is easily activated, meaning it has an electrochemical potential of -1.5 to -0.5V. - It is stable, meaning that no decomposition products are produced.

[0010] More specifically, the compounds of the present invention exhibit either one low reversible reduction peak or two reversible reduction peaks separated by at least 0.1 V, preferably at least 0.3 V, more preferably at least 0.4 V, and even more preferably at least 0.5 V (the first reversible reduction peak being low).

[0011] Therefore, the present invention relates to an electrochromic compound of formula (I) as defined below.

[0012] The present invention also relates to an electrochromic composition comprising at least one compound of formula (I).

[0013] Finally, the present invention relates to an electrochromic device, such as an ophthalmic lens, comprising an electrochromic compound or electrochromic composition of formula (I) of the present invention. [Modes for carrying out the invention]

[0014] 1.Definition The term "aromatic compound" refers to an unsaturated chemical compound characterized by one or more planar rings of atoms bonded together by covalent bonds.

[0015] The term "cyclic compound or ring compound" corresponds to a compound in which one or more atoms in the compound are connected in a row to form a ring. The ring can vary in size from 3 to a large number of atoms, for example 5 or 6 atoms, and includes examples where all atoms are carbon (i.e., a carbocyclic ring) or examples where both carbon and non-carbon atoms are present (heterocyclic compound). More precisely, a "heterocyclic compound or ring structure" is a cyclic compound having atoms of at least two different elements as members of the ring.

[0016] The term "azole" represents any 5-membered heterocyclic radical containing a nitrogen atom and at least one other non-carbon atom as part of the ring. Examples of other non-carbon atoms include nitrogen, oxygen, sulfur, and selenium. The 5-membered heterocycle (ring C5) in the present invention is typically an azole. Examples of azole groups include imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, selenazole.

[0017] The term "condensed system" refers to a system in which p-orbitals having delocalized electrons in the molecule are connected, and generally can lower the energy of the whole molecule and enhance stability. This has conventionally been expressed as having alternating single bonds and multiple bonds. Lone pairs, radicals or carbocations can be part of cyclic, acyclic, linear or mixed systems. The conjugated system according to the present invention formed by a 5-membered heterocycle (ring C5) and a 6-membered (hetero)ring (ring C6) is, for example, benzazole (or benzoxazole), benzoisoxazole, benzothiazole, benzimidazole, indazole, imidazo[1,2-a]pyridine.

[0018] The term "pyridinium" refers to the cation of pyridine in which the nitrogen atom is positively charged, and is represented by the following formula:

Chemical formula

[0019] "Alkyl" or "C1~ 18 The term "alkyl" refers to any monovalent radical of a linear or branched hydrocarbon chain containing 1 to 18 carbon atoms. The term "C3-C6 alkyl" refers to an alkyl group with 3 to 6 carbon atoms. 18 Examples of alkyl groups include C1-C4 alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, or t-butyl; C6-C8 alkyl groups such as n-hexyl, n-heptyl, or n-octyl; and groups such as n-pentyl, 2-ethylhexyl, 3,5,5-trimethylhexyl, nonyl, n-decyl, n-undecyl, n-dodecyl, or n-octadecyl.

[0020] The term "aryl" refers to any monovalent radical of a monocyclic or polycyclic aromatic hydrocarbon containing 6 to 18 carbon atoms. The term "polycyclic aryl or polycyclic aromatic compound" refers to either a compound in which at least one carbon-carbon bond is shared between two aromatic rings (condensed aromatic ring) or a polycyclic aromatic hydrocarbon containing two or more benzenoid rings linked by carbon-carbon single bonds. C6~C 18 Examples of aryl groups include phenyl, naphthyl, anthracenyl, and phenantrenyl.

[0021] The term "arylalkyl" refers to any of the aryl derivatives of an alkyl group. The term "arylalkyl" refers to a combination of the aryl group defined above with the alkyl group defined above. Examples of arylalkyls include benzyl, phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl, naphthylmethyl, naphthylethyl, naphthylpropyl, naphthylbutyl, naphthylpentyl, naphthylhexyl, anthracenylmethyl, anthracenylethyl, anthracenylpropyl, anthracenylbutyl, anthracenylpentyl, anthracenylhexyl, phenanthrenylmethyl, phenanthrenylethyl, phenanthrenylpropyl, phenanthrenylbutyl, phenanthrenylpentyl, and phenanthrenylhexyl.

[0022] The term "heteroaryl" refers to any monovalent radical of a monocyclic or polycyclic 5-10 membered aromatic group containing 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur. 10 Examples of heteroaryl groups include furyl, thienyl, pyrrolyl, pyrazoyl, imidazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1-benzofuryl, 1-benzothienyl, indolyl, benzimidazolyl, indazolyl, 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, benzothiazolyl, benzoxazolyl, benzotriazolyl, pyridyl, pyridinium, quinolinyl, quinolinium, isoquinolinyl, isoquinolinium, pyridadinyl, cinolinyl, phthaldinyl, pyrimidinyl, quinazolyl, pyrazinyl, and quinoxalinyl.

[0023] Unless otherwise specified, the groups and radicals defined herein are unsubstituted or may be substituted with one or more substituents such as halogens, alkyls, alkoxys, aryls, heteroaryls, haloalkyls, haloalkoxys, alkoxycarbonyls, alkanoyls, aroyls, formyls, nitriles, nitros, amides, alkylthios, alkylsulfinyls, alkylsulfonyls, arylthios, arylsulfinyls, arylsulfonyls, aminos, alkylaminos, arylaminos, dialkylaminos, and dialkylaminos.

[0024] These substituents are not phosphonate groups (P=O(OR)(OR') (where R and R' are either alkyl or aryl), phosphate groups, carboxyl groups (C=O(OH)), trihalosilyl groups such as trichlorosilyl groups, trialkoxysilyl groups (triethoxysilyl group, trimethoxysilyl group, etc.), monohalosilyl groups (monochlorosilyl group, etc.), or monoalkoxysilyl groups.

[0025] Electrochromic compounds The electrochromic compounds of the present invention have a central core containing a five-membered heterocycle, typically a five-membered heterocycle in which an azole ring is fused to a six-membered (hetero) ring, on which one or more lateral pyridinium groups, particularly 1, 2, or 3 lateral pyridinium groups, branch thereon.

[0026] Thus, the electrochromic compound of the present invention is of formula (I): [ka] (In the formula, A is N, + N, N-R1, + It is N-R1 or C-R1, B is C-R2, S, Se, O, N, N-R2 or + It is N-R2, D is C-R3, N, S, O, Se, N-R3 or + It is N-R3, E is C, N or + N is, R1 is H, C1~ 18 Alkyl, aryl, or Z, R2 is H, C1~ 18 Alkyl, aryl, Z, or aryl substituted with Z, R3 is H or C1~ 18 Alkyl, aryl, or Z, R4 is H, C1~ 18 Alkyl, aryl, or Z, R5 is H, C1~ 18 Alkyl, aryl, or Z, R6 is H, C1~ 18 Alkyl, aryl, or Z, R7 is H, C1~ 18 Alkyl, aryl, or Z, R7 and R6, and / or R6 and R5, and / or R5 and R4, may optionally be substituted by Z to form together aromatic or heteroaromatic rings condensed on the 6-membered (complex) cyclic core (ring C6) to which they are bonded. Here, Z is, [ka] And, Y is C1~ 18 Alkyl, (hetero)aryl, or (hetero)arylalkyl, R8, R9, R 10 and R 11 H and C1~ 18 Selected independently of alkyl, R8 and R9 or R 10 and R 11 These can form aromatic rings condensed with the pyridium groups to which they are bonded. In the case of B=CZ and A= + In the case of N, R8 or R 11 Together with A, it can form an aromatic or non-aromatic ring fused with the 5-membered heterocycle (ring C5) to which A is bonded. n is chosen to balance the number of positive charges. X is the counterion, [ka] These are single or double bonds, However, the following three points apply: 1) Ring C5 is a 5-membered heterocyclic ring, and A, B, D, and two E are N, N-R1. + N-R1, N-R2, + N-R2, N-R3, + To be selected independently from N-R3, S, Se, and O. 2) Rings C5 and C6 form a conjugated system, and 3) At least one of R1, R2, R3, R4, R5, R6, or R7 is Z, or at least R7 and R6 together form an aromatic ring substituted by Z, or at least R5 and R6 together form an aromatic ring substituted by Z, or at least R5 and R4 together form an aromatic ring substituted by Z. (Conditional conditions apply) It is represented by [this].

[0027] In all aspects of the present invention, unless otherwise specified, Y is preferably a C1-6 alkyl or aryl, for example, Y is methyl, n-hexyl, or phenyl.

[0028] In all aspects of the present invention, the counterion X- can be selected from halides, preferably fluorides and chlorides, tetrafluoroborates, tetraphenylborates, hexafluorophosphates, nitrates, methanesulfonates, trifluoromethanesulfonates, p-toluenesulfonates, hexachloroantimonates, bis(trifluoromethanesulfonyl)imides, perchlorates, acetates, and sulfates, but preferably X - These are tetrafluoroborate or hexafluorophosphate.

[0029] The electrochromic compounds of the present invention are typically of formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), or (X): [ka] [ka] [ka] [ka] (In the formula, A, B, D, E, R1, R2, R3, R4, R5, R6, R7, R8, R, R 10 and R 11 (If any exist) and Z, Y, n, and X are as described above.) It is represented by [this].

[0030] In a preferred embodiment of the present invention, the five-membered heterocyclic ring C5 at the core of the electrochromic compound is an azole ring, and the compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), or (X) are - A is N, + N, N-R1 or + N-R1 and / or - B is N, N-R2 or + N-R2 and / or - D is N, N-R3 or + It is N-R3. It is.

[0031] Preferred compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), or (X) are those in which E is N or + It may be N and / or D may be S.

[0032] The compound of formula (I) may be, for example, the following: - A + N is R1, B is C-R2, D is S or N-R3, E is C, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11, Z, Y, n and X are as defined above, - A + N is R1, B is C-R2, D is C-R3, E is N, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11 , Z, Y, n and X are as defined above, - A is N, B is C-R2, D is Se or O, E is C, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11 , Z, Y, n and X are as defined above, - A is C-R1, and B is N or + N-R2, D is S, E is C, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11 , Z, Y, n and X are as defined above, - A is C-R1, B is N, D is O, E is C, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11 , Z, Y, n and X are as defined above, - A is C-R1, and D is N. + N is R3, S, Se or O, E is C, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11 , Z, Y, n and X are as defined above, - B is N or + N is R2, A is C-R1, D is C-R3, E is N, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11 , Z, Y, n and X are as defined above, - D + N-R3 or N, A is C-R1, B is C-R2, E is N, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11, Z, Y, n and X are as defined above, or - E + N is, A is O, S or Se, B is C-R2, D is C-R3, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R 11 , where Z, Y, n and X are as defined above.

[0033] In one modified form of the present invention, the compound of the present invention is of formula (II), where A is N, + N, N-R1 or + N is R1, and D is N-R3. + N is R3, S, Se or O, E is C, and R1, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 Z, Y, n, and X are as defined above.

[0034] In one modified form of the present invention, the compound of formula (II) is such that A is N + or + N-R1, D is S, E is C, and R1, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 Z, Y, n, and X are as defined above.

[0035] According to this particular embodiment, the compound may be of formula (II), where A is + N-R1, D is S, E is C, and R1 is C1~C 18 It is an alkyl group, preferably R1 is a C1-6 alkyl group, more preferably R1 is methyl, and R4 is preferably H, C1- 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R6 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R6 is H, and R7 is preferably H, C1~ 18is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18 is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 is alkyl or aryl, more preferably R9 is H, and R 10 is preferably H, C1~ 18 is alkyl or aryl, more preferably R 10 is H, and R 11 is preferably H, C1~ 18 is alkyl or aryl, more preferably R 11 is H, and Y is preferably C1~ 18 is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is n-hexyl or phenyl, n is 2, and X - is tetrafluoroborate or hexafluorophosphate, preferably tetrafluoroborate.

[0036] Other preferred compounds according to this particular embodiment are typically those of formula (II) in which A is + N, D is S, E is C, and R8, together with A, forms an unsaturated or non-unsaturated 5- or 6-membered ring fused to the ring C5 to which A is attached, and is represented by formula (XI), (XII) or (XIII).

Chemical formula

[0037] Furthermore, according to this embodiment, preferred compounds are those in which A is [[ID=4{2]] + N-R1, D is S, E is C, and R1, R4, R5, R6, R7, R8, R9, R 10 R 11, Z, Y, n and X may be of formula (II) as defined above. More specifically, these compounds are of formula (II), where R7 and R6, and / or R6 and R5, and / or R5 and R4 are optionally substituted with Z, together forming an aromatic ring or heteroaromatic ring condensed to the (hetero)cyclic core (ring C6) to which they are bonded, and Z, R1, R8, R9, R 10 , R 11 Z, Y, n, and X are as defined above. A specific example is shown below. [ka]

[0038] The compounds according to this embodiment are R8 and R9 or R 10 and R 11 However, these groups form aromatic rings condensed on the pyridium groups to which they are attached, and R1, R4, R5, R6, R7, Z, Y, n, and X are as defined above. Examples of such compounds are shown below. [ka]

[0039] In this particular embodiment, R1 is preferably C1~ 18 It is an alkyl group, more preferably R1 is a C1-6 alkyl such as methyl, and R4 is preferably H, C1- 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R6 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R6 is H, and R7 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is phenyl, n is 2, and X - These are tetrafluoroborate or hexafluorophosphate.

[0040] In a second embodiment of this particular variant, the compound of formula (II) is A + N is R1, D is N-R3, E is C, and R1, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 Z, Y, n, and X are as defined above.

[0041] According to this particular embodiment, Compound A is + N is R1, D is N-R3, E is C, and R1 is C1~ 18 It is an alkyl group, preferably where R1 is a C1-6 alkyl such as methyl or n-hexyl, and R4 is H, C1- 18 It is alkyl or aryl, preferably R4 is H, R5 is H, C1~ 18 It is alkyl or aryl, preferably R5 is H, R6 is H, C1~ 18 It is alkyl or aryl, preferably R6 is H, R7 is H, C1~ 18 It is alkyl or aryl, preferably R7 is H, R8 is H, C1~ 18 It is alkyl or aryl, preferably R8 is H, R9 is H, C1~ 18 It is alkyl or aryl, preferably R9 is H, and R 10 H, C1~ 18 It is alkyl or aryl, preferably R 10 H is R 11 H, C1~ 18It is alkyl or aryl, preferably R 11 H is and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is methyl, n-hexyl or phenyl, n is 2, and X - It may be a substance of formula (II) in which is a tetrafluoroborate or hexafluorophosphate, preferably a hexafluorophosphate.

[0042] Other preferred compounds according to this particular embodiment are typically A + N-R1, D is N-R3, E is C, and R7 and R6, and / or R6 and R5, and / or R5 and R4 are optionally substituted by Z, forming together aromatic rings or heteroaromatic rings condensed on a (complex) cyclic core (ring C6) to which they are bonded, and R1, R3, R8, R9, R 10 , R 11 The compound is of formula (II), where Z, Y, n, and X are as defined above. Examples of such compounds are shown below. [ka]

[0043] In this particular embodiment, R1 is preferably C1~ 18 It is an alkyl group, more preferably R1 is a C1-6 alkyl group such as methyl, and R3 is preferably C1- 18 R3 is an alkyl or optionally substituted aryl, more preferably R3 is an optionally substituted aryl such as 4-t-butylphenyl, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, and Y is preferably C1~ 18Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is methyl, n is 4, and X - These are tetrafluoroborate or hexafluorophosphate.

[0044] In a third embodiment of this particular variant, the compound of formula (II) is such that A is N, D is Se, E is C, and R4, R5, R6, R7, R8, R9, R 10 , R 11 Z, Y, n, and X are as defined above.

[0045] According to this third embodiment, the compound is such that A is N, D is Se, E is C, R4 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R6 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R6 is H, and R7 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, 10 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 10 H is R 11 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 11 H is and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is n-hexyl or phenyl, n is 2, and X -It may be a compound of formula (II) in which is a tetrafluoroborate or a hexafluorophosphate.

[0046] In this particular variant, in the fourth embodiment, the compound of formula (II) is such that A is N, D is O, E is C, and R4, R5, R6, R7, R8, R9, R 10 , R 11 Z, Y, n, and X are as defined above.

[0047] According to this fourth embodiment, the compound is such that A is N, D is O, E is C, R4 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R6 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R6 is H, and R7 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, 10 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 10 H is R 11 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 11 H is and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is n-hexyl or phenyl, n is 2, and X - It may be a compound of formula (II) in which is a tetrafluoroborate or a hexafluorophosphate.

[0048] In a second modified form of the present invention, the compound of the present invention is A + N is R1, D is C-R3, E is N, and R1, R4, R5, R6, R7, R8, R9, R 10 , R 11 The equation (II) is one in which Z, Y, n, and X are as defined above.

[0049] According to this modified form, the compound of the present invention preferably has R1 as C1~ 18 It is an alkyl group, more preferably R1 is a C1-6 alkyl group such as methyl, and R3 is preferably H or C1- 18 It is alkyl, more preferably R3 is H, and R4 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R6 is preferably C1~ 18 R6 is alkyl, aryl, or Z, more preferably R6 is aryl or Z, and R7 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, 10 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 10 H is R 11 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 11 H is and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is n-hexyl or phenyl, n is preferably 2 or 3, and X - This is a tetrafluoroborate or hexafluorophosphate.

[0050] In a third variant of the present invention, the compound of the present invention is such that B is N or + N-R2, D is S, E is C, and R2, R4, R5, R6, R7, R8, R9, R 10 , R 11 The equation (III) is one in which Z, Y, n, and X are as defined above.

[0051] According to this third variant of the present invention, the compound of the present invention preferably has R2 (if present) as C1~ 18 It is an alkyl group, more preferably R2 is a C1-6 alkyl group such as methyl, and R4 is preferably H, C1- 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R6 is preferably C1~ 18 It is alkyl, aryl, more preferably R6 is H, and R7 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, 10 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 10 H is R 11 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 11 H is and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is n-hexyl or phenyl, n is 1 or 2, and X - This may be a tetrafluoroborate or a hexafluorophosphate.

[0052] In a fourth variant of the present invention, the compound of the present invention is characterized in that B is N, D is O, E is C, and R2, R4, R5, R6, R7, R8, R9, R 10 , R 11 The equation (III) is one in which Z, Y, n, and X are as defined above.

[0053] According to this fourth variant of the present invention, the compound of the present invention is preferably R4 is H, C1~ 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R6 is preferably C1~ 18 It is alkyl, aryl, more preferably R6 is H, and R7 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, 10 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 10 H is R 11 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 11 H is and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is n-hexyl or phenyl, n is 1, and X - This may be a tetrafluoroborate or a hexafluorophosphate.

[0054] In a fifth variant of the present invention, the compound of the present invention is A + N is R1, B is C-R2, D is C-R3, E is N, and R1, R2, R3, R4, R5, R7, R8, R9, R 10 , R11 The equation (V) is one in which Z, Y, n, and X are as defined above.

[0055] According to this fifth variant of the present invention, the compound of the present invention is preferably such that R1 is C1~ 18 It is an alkyl group, more preferably R1 is a C1-6 alkyl group such as methyl, and R2 is preferably C1- 18 It is alkyl or aryl, more preferably R2 is an aryl such as phenyl, and R3 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R3 is H, and R4 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R4 is H, and R5 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R5 is H, and R7 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R7 is H, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, 10 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 10 H is R 11 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 11 H is and Y is preferably C1~ 18 Y is alkyl or aryl, more preferably Y is C1-6 alkyl or aryl, even more preferably Y is n-hexyl or phenyl, n is 2, and X - This may be a tetrafluoroborate or a hexafluorophosphate.

[0056] In the sixth variant of the present invention, the compound of the present invention is such that A is N-R1, B is C-R2, D is C-R3, E is N, and R1, R2, R3, R8, R9, R10 , R 11 , Z, Y, n and X are as defined above in equation (IX) or (X).

[0057] According to this sixth variant of the present invention, the compound of the present invention is preferably such that R1 is C1~ 18 It is an alkyl group, more preferably R1 is a C1-6 alkyl such as methyl, R2 is preferably a substituted aryl, more preferably R2 is 4-t-butylphenyl or a phenyl substituted with Z, and R3 is preferably C1- 18 It is alkyl or aryl, more preferably R3 is aryl, for example 4-t-butylphenyl, and R8 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R8 is H, and R9 is preferably H, C1~ 18 It is alkyl or aryl, more preferably R9 is H, 10 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 10 H is R 11 Preferably H, C1~ 18 Alkyl or aryl, more preferably R 11 H is and Y is preferably C1~ 18 It is alkyl or aryl, more preferably Y is a C1-6 alkyl such as methyl, n is 3 or 4, and X - This may be a tetrafluoroborate or a hexafluorophosphate.

[0058] In a particularly preferred embodiment of the present invention, the compound of formula (I) is selected from the group consisting of the following:

[0059] [Table 1]

[0060] [Table 2]

[0061] [Table 3]

[0062] [Table 4]

[0063] [Table 5]

[0064] The compound represented by formula (I) can be prepared according to various methods well known in the art.

[0065] For example, the compound represented by formula (I) can be obtained according to the synthetic route detailed below.

[0066] Various pathways for accessing benzimidazole and benzothiazole derivatives have been reported. The simplest and most useful pathways involve cyclizing heterocycles to 1,2-phenylenediamine or 2-aminothiophenol, respectively. Synthetic pathways involving these precursors have been reviewed (J. Revuelta, F. Machetti and S. Cicchi in Modern Heterocyclic Chemistry eds. J. Alvarez-Builla, J.J. Vaquero and J. Barluenga, Wiley-WCH, Weinheim, 2011, vol.2, pp.809-923).

[0067] 2-(hetero)arylbenzothiazoles can be obtained via the tandem acylation-dehydration cyclization reaction of 2-aminothiophenol, but other routes are known. For example, 2-(4-pyridyl)benzothiazole can be obtained by first reacting 4-picoline and sulfur at high temperature in the presence of aniline, or by reacting isonicotinic acid and 2-aminothiophenol in the presence of thionyl chloride. Furthermore, the same compound can be obtained by the cyclization condensation of 2-aminothiophenol and pyridine-4-carboxyaldehyde, followed by oxidation of benzothiazoline with iron(III) sulfate (PEMiller, GLOliver, JRDann and JWGates Jr., J.Org.Chem., 1957, 22, 664). More recently, it has been shown that benzothiazoles can also be obtained from aldehydes or alkanophenones and 2-aminothiophenol. The oxidation step is achieved by air oxidation in DMSO (Y. Liao, H. Qi, S. Chen, P. Jiang, W. Zhou and G.-J. Deng, Org. Lett., 2012, 14, 6004). In this study, these approaches were combined by stirring an ethanolic solution of 2-aminothiophenol and pyridine-4-carboxyaldehyde in air. Subsequently, N-alkylation with a haloalkane, such as 1-iodohexane, proceeded readily at the pyridine moiety, as expected (K. Halman and OH Hankovszky, Acta Chim. Acad. Sci. Hung., 1965, 43, 263; P. Zavins E. S. Lavinovitch and A. Arens, Khim. Geterotsikl. Soedin., 1973, 104). Thus, 1-iodohexane yielded a high yield of iodide salts, and ultimately, tetrafluoroborate was obtained by subsequent anion exchange. The latter could be further alkylated at N-3 of the benzothiazole moiety with methyl tosylate, as shown in Scheme 1. [ka]

[0068] 2-(1-phenylpyridine-4-yl-1-ium)benzothiazole has been synthesized in complex sequences using pyrium salt chemistry (GNDorofeenko, AVKoblik, BATertov and TIPolyakova, Khim.Geterotsikl.Soedin., 1973, 1016), but a simpler approach to this salt and its derived salts is shown in Scheme 6. A key step involves N-arylation of the pyridine moiety with readily available diphenyliodonium triflate (M.Bielawski and B.Olofsson, Chem.Commun., 2007, 2521) under copper catalyst. This method has been used for the N-phenylation of various other heterocyclic systems (T.Lv, Z.Wang, J.You, J.Lan and G.Gao, J.Org.Chem., 2013, 73, 5723; C.Reus, M.Stolar, J.Vanderkley, J.Neubauer and T.Baumgartner, J.Am.Chem.Soc., 2015, 137, 11710). The alkylation of benzothiazole by methyl tosylate proceeds straightforwardly. [ka]

[0069] Sequences similar to those depicted in Schemes 1 and 2 can be applied to readily available quinoline-4-carbaldehyde (W.-Z.Weng, J.-S.Guo, K.-X.Liu, T.-Q.Shao, L.-Q.Song, Y.-P.Zhu, Y.-Y.Sun and Q.-G.Meng, Can.J.Chem., 2020, 98, 179) and derived benzothiazoles.

[0070] While accessible from o-phenylenediamine (OPD) and carboxylic acid derivatives, 2-(2-pyridyl)- and 2-(4-pyridyl)-benzimidazoles were efficiently obtained by condensation-air oxidation of OPD with a suitable pyridinecarboxaldehyde (see S. Haneda, Z. Gan, K. Eda and M. Hayashi, Organometallics, 2007, 26, 6551). The imidazole ring of 2-(4-pyridyl)benzimidazole could be selectively methylated by treatment with MeI under basic conditions. Sequential alkylation of the pyridine moiety and the benzimidazole ring was achieved. Using the same method as before, the pyridine moiety of 1-methyl-2-(4-pyridyl)benzimidazole was N-arylated with diphenyliodonium triflate via Cu, followed by treatment with haloalkanes or MeOTs to obtain a series of novel compounds (Scheme 3). [ka]

[0071] Imidazo[1,2-a]pyridine can be obtained through various routes, and many reviews on the synthesis and chemistry of these compounds are available (HLBlewitt in Special Topics in Heterocyclic Chemistry eds. A. Weissberger and ECTaylor, Wiley-Interscience, New York, 1977, pp. 117-178; F. Couty and G. Evano, Comprehensive Heterocyclic Chemistry III eds. ARKatritzky, CAramsden, EFF Scriven and RJK Taylor, Elsevier, Oxford, 2008, vol. 11, pp. 409-499; AKBagdi, S. Santra, K. Monir and A. Hajra, Chem.Commun., 2015, 51, 1555; SMRoopan, SMPatil and J. Palaniraja, Res. Chem. Intermed., 2016, 42, 2740). N-alkylation-recyclization condensation of 2-aminopyridine and α-bromoketone is the most useful entry point to these bicyclic rings. Thus, the reaction of commercially available 2-amino-4-bromopyridine with phenacyl bromide in methanol in the presence of NaHCO3 yielded 7-bromo-2-phenylimidazo[1,2-a]pyridine A [KCLLee and ETSun, International Publication No. 2006 / 101455A1 pamphlet (2006)]. A similar reaction using 4-(bromoacetyl)pyridine hydrobromide instead of phenacyl bromide (MPHay, S. Turcette, JUFlannagan, M. Bonnet, DAChan, PDSutphin, P. Nguyen, AJGraccia and WADenny, J.Med.Chem., 2010, 53, 787) yielded 7-bromo-2-(4-pyridyl)imidazo[1,2-a]pyridine B in good yield.Suzuki-Miyaura coupling of A and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine yielded 2-phenyl-7-(4-pyridyl)imidazo[1,2-a]pyridine C in high yield. This Pd-coupling reaction was applied to B to produce the 7-phenyl derivative D and the bis-pyridyl compound E. Alkylation of C and D with 1-iodohexane in MeCN proceeded at the pyridine nitrogen, yielding salts F and G, respectively. Further alkylation of F and G at N-1 was achieved by heating with methyl tosylate. Bis-alkylation of both pyridine moieties in E was achieved by heating with excess alkyl halide to obtain H. H can be methylated at N-1 with methyl tosylate (Scheme 4). [ka]

[0072] 4,4'-Dibromobenzyl is widely available commercially, and its isomers are dibromophenanthrene-9,10-dione and 3,6-dibromophenanthrene-9,10-dione (MOBaniKhaled, JDMottishaw, H.Sun, Cryst.Growth). Des.,2015,15,2235;A.Patel,SYSharp,K.Hall,W.Lewis,MFGStevens,P.Workman,CJMoody,Org.Biomol.Chem.,2016,14,3889) and 2,7-dibromophenanthrene-9,10-dione (THVo,M.Shekhirev,DAKunkel,F.Orange,MJ-F.Guinel,A.Endersbe,A.Sinitskii,Chem.Commun.,2014,50,4172) were prepared by selective bromination of phenanthrene-9,10-dione according to the procedures in the published literature.

[0073] Multicomponent condensation reactions between 1,2-dicarbonyl compounds, aromatic aldehydes, aniline, and low-molecular-weight molecules capable of supplying nitrogen atoms, such as ammonium acetate, carried out in a suitable medium, are a versatile pathway to highly substituted imidazoles and condensed imidazoles (K.Skonieczny, DTGryko, J.Org.Chem., 2015, 80, 5753; MMHeravil, M.Daraiel, V.Zadsirjan, Mol.Divers., 2015, 19, 577; D.Kumar, KRJThomas, J.Photochem.Photobiol.A:Chem., 2011, 218, 162). The synthesis of 6,9-dibromo-1,2-bis(4-(tert-butyl)phenyl)-1H-phenanthro[9,10-d]imidazole is achieved by multicomponent condensation between 3,6-dibromophenanthrene-9,10-dione, 4-tert-butylbenzaldehyde, 4-tert-butylaniline, and ammonium acetate in acetic acid (WC.Chen, Y.Yuan, Y.Xiong, ALRogach, QX.Tong, CS.Lee, ACS Appl.Mater.Interfaces, 2017, 9, 26268). Using the same reaction conditions and reagents, 2,7-dibromophenanthrene-9,10-dione was converted to 5,10-dibromo-1,2-bis(4-(tert-butyl)phenyl)-1H-phenanthro[9,10-d]imidazole (Scheme 5). [ka]

[0074] The multicomponent condensation shown in Scheme 1 is repeated, but starting with 3,6-dibromophenanthrene-9,10-dione and using 4-bromobenzaldehyde or pyridine-4-carboxyaldehyde as the aldehyde component, 6,9-dibromo-2-(4-bromophenyl)-1-(4-(tert-butyl)phenyl)-1H-phenanthro[9,10-d]imidazole or 6,9-dibromo-1-(4-(tert-butyl)phenyl)-2-(pyridine4-yl)-1H-phenanthro[9,10-d]imidazole are obtained (Scheme 6). [ka]

[0075] The aforementioned bromosubstituted imidazole and phenantro[9,10-d]imidazole were subjected to a general Suzuki cross-coupling protocol with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine using a carbonate base in a mixed solvent system with a palladium catalyst, typically tetrakis(triphenylphosphine)palladium(0), to obtain poly(4-pyridyl)substituted imidazole and phenantro[9,10-d]imidazole (Scheme 7). Suzuki coupling of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine with aryl bromide has been widely reported (M. Juricek, JC Barnes, EJ Dale, WG. Liu, NL Strutt, CJ Bruns, NA Vermeulen, KC Hooray, AAS Arjeant, CLStern, YY Botros, WA Goddard, JFS Toddart, J. Am. Chem. Soc., 2013, 135, 12736; Y. Nakamura, N. Aratani, A. Osuka, Chem. Asian J.,2007,2,860;V.Gray,K.Boerjesson,D.Dzebo,M.Abrahamsson,B.Albinsson,K.Moth-Poulsen,J.Phys.Chem.C,2016,120,19018) (Scheme 7). [ka]

[0076] Methyl tosylates have been used as effective methylating agents in neat or co-solvent form (JFSCarvalho, J.Louvel, MLJDoornbos, E.Klaase, Z.Yu, J.Brussee, A.P.Jzerman, J.Med.Chem., 2013, 56, 2828; ANWodward, JMKolesar, SRHall, NA.Saleh, DSJones, MGWalter, J.Am.Chem.Soc., 2017). (139,8467; L. Pescatori, A. Arduini, A. Pochini, A. Secchi, C. Massera, F. Ugozzoli, Org. Biomol. Chem., 2009, 7,3698; M. Kuroboshi, T. Yamamoto, H. Tanaka, Synlett, 2013, 24,0197; JAZoltewicz, MPCruskie, Jr., Tetrahedron, 1995, 51,3103). In this study, the N atom of the pyridine ring and N3 of the imidazole ring were simultaneously N-methylated using methyl tosylate. The resulting poly(tosylate) salt was directly converted to a fluoroborate salt (Scheme 8). [ka]

[0077] 2-(pyridine-4-yl)benzoserenazole was synthesized according to the procedure in the modified literature (T.Su, S.Xie, B.Li, J.Yan, L.Huang, X.Li, Synlett 2015;26,215). The pyridine N-atom of 2-(pyridine-4-yl)benzoserenazole was selectively alkylated by reacting it with a suitable alkyl halide (Scheme 11). Alternatively, the pyridine N atom arylation of 2-(pyridine-4-yl)benzoserenazole was performed using aryliodonium salts according to a standard literature protocol (T.Lv, Z.Wang, J.You, J.Lan and G.Gao, J.Org.Chem., 2013, 73, 5723; C.Reus, M.Stolar, J.Vanderkley, J.Neubauer and T.Baumgartner, J.Am.Chem.Soc., 2015, 137, 11710). Finally, the desired electrochromic compound was obtained by counterion exchange with NaBF4 or NH4PF6 (Scheme 9). [ka]

[0078] Benzooxazoles can be accessed via a similar pathway to benzothiazoles. Condensation of 2-aminophenol and pyridine-4-carboxyaldehyde in the presence of air yields 2,3-dihydrobenzoxazole derivatives. Subsequent dehydrogenation to 2-(4-pyridyl)benzoxazole is readily achieved by treating 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in dichloromethane. N-alkylation and N-arylation of the pyridine moiety can be performed using standard procedures (Scheme 10). [ka]

[0079] Numerous methods are available to construct other condensed cyclic azoles. For example, 2-arylnaphtho[1,2-d]thiazole can be accessed via a one-pot dehydrogenation (Semmler-Wolff aromatization)-sulfur transfer-cyclization condensation sequence between 1-tetralonoxime O-acetate and an arylaldehyde in DMSO in the presence of elemental sulfur (Z.Xu, H.Huang, H.Chen and G.-J.Deng, Org.Chem.Front., 2019, 6, 3060). Thus, 2-(pyridine-4-yl)benzothiazole was obtained, and the pyridine moiety was selectively N-arylated using diphenyliodonium triflate under copper catalysis by conventional methods. Subsequently, N-methylation of the thiazole ring was achieved by treatment with MeOTf (Scheme 11). These quaternization reactions are widely applicable to other diheterocyclic systems. [ka]

[0080] 3-aryl-1,2-benzisothiazoles, including 3-(pyridine-4-yl) derivatives, can be accessed by quenching a thioanisole dianion (obtained by lithiation with BuLi-TMEDA in TBME) with 4-pyridinecarbonitrile (R.Zhu, Z.Liu, J.Chen, X.Xiong, Y.Wang, L.Huang, J.Bai, Y.Deng and J.Huang, Org.Lett., 2018, 20, 3161) (Scheme 12). [ka]

[0081] 3-(hetero)aryl-1,2-benzisoxazole can be readily obtained by intramolecular cyclization of oximes or imines obtained from 2-halogeno or 2-hydroxybenzophenone (see F. Gualtieri and M. Giannalla in Isoxazoles eds. P. Gruenanger and P. Vita Finzi, Chemistry of Heterocyclic Compounds, John Wiley & Sons Inc., 1999, vol. 48, part 2, p. 1 for a review). 3-(pyridine-4-yl)-1,2-benzisoxazole was prepared by oxidative cyclization of an imine derived from 4-(2-hydroxybenzoyl)pyridine with N-chlorosuccinimide according to a literature-based procedure (Scheme 13) (H. Hepburn and TJ Donohoe, Chem. Eur. J., 2020, 26, 1963). [ka]

[0082] Electrochromic composition The present invention also relates to an electrochromic composition comprising at least one compound of formula (I) as defined above as an oxidizing electrochromic compound. One or more additional oxidizing electrochromic compounds may be added to the composition of the present invention to adapt the intensity of the color or coloring state of the composition of the present invention. The additional compounds may be other compounds of formula (I) or other compounds such as compatible dyes or pigments. For example, the additional oxidizing electrochromic compounds may be selected from alkyl viologens, aryl viologens, alkylaryl viologens, or anthraquinones and derivatives. Preferably, the additional compounds have an oxidation-reduction potential close to that of the compounds of formula (I).

[0083] The composition may also contain at least one reducing compound. The reducing compound may also be an electrochromic compound. Examples of reducing compounds include 5,10-dihydrophenazine, phenothiazine, phenoxazine, N,N,N',N'-tetramethyl-p-phenylenediamine, thioanthrene, tetrathiafulvalene, ferrocene, and their derivatives.

[0084] The compositions of the present invention may include a host medium, which may be a fluid, a liquid crystalline medium, or a gel. The host medium is introduced into the composition of the present invention to dissolve the electrochromic compound. The host medium is preferably selected from the group consisting of organic solvents, liquid crystals, polymers, liquid crystalline polymers, and mixtures thereof.

[0085] Suitable organic solvents that can be used as host media include redox-compatible solvents that do not react with the electrochromic compound of the composition, such as ethylene carbonate, propylene carbonate, γ-butyrolactone, γ-valerolactone, acetoronitrile, propionitrile, benzonitrile, glutaronitrile, methylglutaronitrile, dimethylformamide, N-methylpyrrolidone, sulfolane, 3-methylsulfolane, benzene, toluene, methyl ethyl ketone, acetone, ethanol, tetrahydrofurfuryl alcohol, 2-methoxyethyl ether, xylene, cyclohexane, 3-methylcyclohexanone, ethyl acetate, ethyl phenylacetate, tetrahydrofuran, methanol, methyl propionate, ethylene glycol, ethylene carbonate, ionic liquids, and mixtures thereof. Carbonates, particularly propylene carbonate, are preferred.

[0086] Suitable examples of liquid crystals that can be used as host media include nematic media or chiral nematic media.

[0087] Examples of suitable polymers that can be used as host media include polymers soluble in solvents, particularly PMMA or other acrylate polymers, polyurethanes, polyethylene oxides, polypropylene oxides, polyvinyl acetates, poly(N-vinylpyrrolidone), and polyvinylidene fluoride.

[0088] Examples of suitable liquid crystal polymers that can be used as host media include Merck RM257 (Merck), LC242 (BASF), or SLM90519 (Wacker). These liquid crystal polymers are generally used in combination with an organic solvent, for example, one of the organic solvents described above.

[0089] Electrochromic device The present invention also relates to an electrochromic device comprising a compound or composition of formula (I) of the present invention. The device can be selected from optical articles, preferably optical lenses or optical filters, windows, preferably aircraft windows, visors, mirrors, and displays, particularly segmented displays or matrix displays. Preferably, the device of the present invention is an optical article, more preferably an optical lens, and even more preferably an ophthalmic lens.

[0090] Non-limiting examples of ophthalmic lenses include corrective and non-corrective lenses, including single-focus or multifocal lenses, which may or may not be segmented. Contact lenses, intraocular lenses, sunglasses, ski goggles, magnifying lenses, protective goggles, and visors, such as motorcycle visors and helmets, and other elements used for vision correction, protection, or enhancement, although not limited thereto, are also included. Non-limiting examples of display elements and devices include screens and monitors. Non-limiting examples of windows include automobile, ship, and aircraft windows, filters, shutters, optical switches, and the like.

[0091] Preferably, the device of the present invention includes a mechanism for holding the compound or composition of the present invention in a mechanically stable environment. More preferably, the device may consist of a pair of opposing substrates having a gap for receiving a mixture of a host medium and the compound or composition of the present invention, and a frame for holding the pair of substrates adjacent to each other.

[0092] Accordingly, the device of the present invention can constitute an optical component comprising at least one array of transparent cells arranged parallel to its surface, as disclosed in International Publication No. 2006 / 013250, each cell being sealed and containing at least one compound or composition of the present invention.

[0093] Another device according to the present invention may be the device described in French Patent No. 2937154 or French Patent No. 2950710, which includes at least one compound of the present invention. [Examples]

[0094] The present invention can be further illustrated by the following non-limiting embodiments, which are provided for illustrative purposes only and do not limit the scope of the appended claims.

[0095] Synthesis of the Compound of the Present Invention 1. Iso) Thiazole benzologue Example 1 2-(pyridine-4-yl)benzothiazole [ka] A solution of 2-aminobenzenethiol (7.01 g, 56.1 mmol) and pyridine-4-carboxaldehyde (6.00 g, 56.1 mmol) in EtOH (28 mL) was stirred under air for 120 hours. The resulting mixture was filtered, the residue was washed with cooled MeOH (20 mL), and the compound was air-dried to obtain the title compound as a creamy powder (7.63 g, 64%). The liquid was filtered under reduced pressure to obtain a second crop (0.73 g, 6%). δ H(CDCl3,400MHz) 7.46 (1H, dt, J=1.2 and 8.2Hz), 7.56 (1H, dt, J=1.2 and 8.2Hz), 7.93-7.99 (3H, m), 8.14 (1H, ddd, J=8.2Hz) and 8.78 (2H, dd, 1.6 and J=4.5Hz); δ C (CDCl3, 100MHz) 121.21, 121.89, 123.93, 126.22, 126.84, 135.21, 140.47, 150.79, 153.97 and 165.11.

[0096] 4-(benzothiazole-2-yl)-1-hexylpyridine-1-ium iodide [ka] A solution of 2-(pyridine-4-yl)benzothiazole (0.54 g, 2.5 mmol) and 1-iodohexane (1.62 g, 7.6 mmol) in MeCN (40 mL) was heated under reflux in the dark under N2 for 24 hours, then cooled and diluted with Et2O (50 mL). The precipitate was filtered, washed with Et2O (3 × 20 mL), and air-dried to obtain the title compound (0.77 g, 71%) as a yellow powder. δ H (DMSO-d6,400MHz)0.85(3H,t,J=7.0Hz),1.21-1.37(6H,m),1.88-2.01(2H,m),4.65(2H,t,J=7.3Hz),7.62-7.72 (2H,m),8.25(1H,dd,J=0.9 and 7.6Hz),8.35(1H,dd,J=1.1 and 7.6Hz),8.76(2H,d,6.8Hz) and 9.23(2H,d,J=6.8Hz);δ C (DMSO-d6, 100MHz) 14.32, 22.34, 25.54, 31.06, 31.19, 61.11, 123.72, 124.82, 125.47, 128.23, 128.33, 136.64, 146.29, 146.73, 153.83 and 161.90.

[0097] 4-(benzothiazole-2-yl)-1-hexylpyridine-1-iumtetrafluoroborate [ka] A solution of 4-(benzothiazole-2-yl-1-hexylpyridine-1-ium iodide (0.77 g, 1.8 mol)) in MeOH / H2O (40 mL, 1:1) was added dropwise to a solution of NaBF4 (3.96 g, 36 mmol) in water (80 mL) with stirring. Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (2 × 5 mL), and air-dried to obtain the title compound (0.69 g, 98%) as a pale yellow powder. δ H (DMSO-d6,400MHz)0.88(3H,t,J=6.9Hz),1.25-1.39(6H,m),1.89-2.02(2H,m),4.67(2H,t,J=7.4Hz),7.64-7. 75(2H,m),8.28(1H,dd,J=1 and 8.3Hz),8.37(1H,dd,J=1 and 7.6Hz),8.79(2H,d,6.8Hz) and 9.23(2H,d,J=6.8Hz);δ C (DMSO-d6, 100MHz) 13.75, 21.78, 24.98, 30.50, 30.63, 60.57, 123.14, 124.26, 124.90, 127.67, 127.77, 136.09, 145.72, 146.19, 153.27 and 161.33.

[0098] Compound 1: 2-(1-hexylpyridine-1-ium-4-yl)-3-methylbenzothiazole-3-iumbis(tetrafluoroborate) [ka] A mixture of 4-(benzothiazole-2-yl)-1-hexylpyridine-1-ium tetrafluoroborate (0.59 g, 1.5 mmol) in MeOTs (1.71 g) was heated at 180°C for 2 hours, then cooled, triturated with Et2O (3 × 40 mL), and dried under N2 to obtain 0.81 g of light yellowish-brown powder. The solid was redissolved in MeOTs (1.71 g), heated at 180°C for 1 hour, cooled, triturated again with Et2O (4 × 30 mL), and air-dried. This gummy solid was dissolved in MeOH / water (25 mL, 1:4) and added dropwise with stirring to a solution of NaBF4 (3.38 g, 30.7 mmol) in water (50 mL). Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (2 × 5 mL), air-dried, and triturated with hot MeOH (8 mL). The residue was cooled, filtered, and washed with cold MeOH (2 mL) to obtain the title compound (0.38 g, 51%) as a cream-colored powder. δ H [(CD3)2CO,400MHz]0.91(3H,t,J=7.0Hz),1.29-1.47(4H,m),1.49-1.61(2H,m),2.20-2.32(2H,m),4.58(3H,s),5.04(2H,t,J=7.7Hz),8 .07(1H,t,J=7.9Hz),8.17(1H,t,J=7.8Hz),8.58(1H,d,J=8.4Hz),8.68(1H,d,J=8.4Hz),8.89(2H,bd,J=5.7Hz) and 9.59(2H,d,J=6.5Hz);δ F [(CD3)2CO,376MHz]-151.40,-151.35;δ C [(CD3)2CO, 100MHz] 13.30, 22.14, 25.54, 30.98, 31.37, 38.42, 62.91, 117.97, 124.70, 129.92, 130.08, 131.05, 131.42, 141.05, 142.81, 146.47 and 168.29.

[0099] Example 2 4-(benzothiazole-2-yl)-1-phenylpyridine-1-ium triflat [ka] 2-(Pyridin-4-yl)benzothiazole (1.34 g, 6.3 mmol), diphenyliodonium triflate (3.47 g, 8.1 mmol), Cu(OAc)₂·H₂O (0.11 g, 0.55 mmol, 10 mol%) in dry DMF (25 mL) was heated at 100 °C for 16 h, cooled, and the solvent was removed under reduced pressure. The residue was triturated with Et₂O (3 × 40 mL) and air-dried to give the title compound (2.66 g, 96%) as a yellow powder. δ H [(CD₃)₂CO, 400 MHz] 7.67 - 7.86 (5H, m), 8.01 - 8.09 (2H, m), 8.27 - 8.37 (2H, m), 9.02 (2H, d, 6.8 Hz) and 9.56 (2H, d, J = 6.8 Hz); δ F [(CD₃)₂CO, 376 MHz] -77.76; δ C (DMSO-d₆, 100 MHz) 122.93, 124.60, 124.85, 125.25, 128.01, 128.18, 130.60, 131.78, 136.92, 142.95, 142.95, 145.92, 148.33, 154.18 and 160.76.

[0100] Compound 2: 3-Methyl-2-(1-phenylpyridin-1-ium-4-yl)benzothiazol-3-ium bis(tetrafluoroborate)

Chem.

[0101] Example 3 (E)-3,4-dihydronaphthalene-1(2H)-one O-acetyloxime [ka] Solid hydroxylamine hydrochloride (7.14 g, 103 mmol) was added all at once to a solution of 3,4-dihydronaphthalene-1(2H)-one (10.00 g, 68.5 mmol) in EtOH (30 mL). The resulting solution was heated at 60°C for 1 hour, added to HCl (200 mL, 2 M), and extracted with siRNA (3 × 50 mL). The combined organic extract was washed with brine (50 mL), then with water (50 mL), dried (Na₂SO₄), and the solvent was removed under reduced pressure. The residue was dissolved in pyridine (32 mL), to which Ac₂O (13.97 g, 137 mmol) and DMAP (16 mg) were added. The resulting solution was stirred at room temperature for 1 hour, added to HCl (300 mL, 2 M), and extracted with siRNA (3 × 200 mL). After drying (Na₂SO₄), the solvent was removed under reduced pressure. The residue was crystallized twice from siRNA / hexane to obtain the title compound (10.51 g, 76%) as a colorless needle-shaped material. δ H(CDCl3,400MHz)1.87-1.93(2H,m),2.27(3H,s),2.77-2.82(2H,br.t,J=6.1Hz),2.86-2.90(2 δ C (CDCl3, 100MHz) 19.92, 21.33, 25.60, 29.55, 125.61, 126.59, 128.72, 128.95, 130.74, 140.93, 161.31 and 169.22.

[0102] 2-(pyridine-4-yl)naphtho[1,2-d]thiazole [ka] Under N2 conditions, a mixture of (E)-3,4-dihydronaphthalene-1(2H)-one O-acetyloxime (4.00 g, 19.7 mmol), pyridine-4-carboxaldehyde (1.40 g, 13.1 mmol), and sulfur (10.09 g, 39.4 mmol) in DMSO (60 mL) was heated at 120 °C for 4 hours, added to water (200 mL), and extracted with SiO2 (3 × 100 mL). The combined extract was washed with water (100 mL), dried, and the solvent was removed under reduced pressure. The residue was chromatographed with silica using SiO2 (hexane gradient 25-30%) as the eluent. The fluorescent band was recovered, and the solvent was removed under reduced pressure. The residue was crystallized from thermal SiO2 / hexane at 0 °C to obtain the title compound (1.14 g, 33%) as a brown needle-shaped material. δ H (CDCl3,600MHz)7.64(1H,ddd,J=1.3,6.9 and 8.1Hz),7.74(1H,ddd,J=1.2,6.9 and 8.2Hz),7.87-7.90(1H,br.dm,J=8.7Hz),7.9 5(1H,d,J=8.7Hz),7.98-8.01(1H,br.m,J=8.1Hz),8.06(2H,d,J=6.0Hz),7.80(2H,d,J=6.0Hz) and 8.93(1H,br.d,J=8.2Hz);δ C(CDCl3, 125MHz) 118.90, 120.98, 123.96, 126.61, 127.17, 127.40, 128.22, 128.92, 132.16, 132.33, 140.77, 150.56, 150.78 and 163.88.

[0103] 4-(Naphtho[1,2-d]thiazole-2-yl)-1-phenylpyridine-1-ium trifluoromethanesulfonate [ka] A mixture of 2-(pyridine-4-yl)naphtho[1,2-d]thiazole (1.12 g, 4.3 mmol), diphenyliodonium trifluoromethanesulfonate (2.20 g, 5.1 mmol), and Cu(OAc)2·H2O (86 mg, 10 mol%) in DMF (30 mL) was heated under N2 at 100 °C for 16 hours. The resulting solution was cooled, and the solvent was removed under reduced pressure. The residue was triturated with Et2O (3 × 30 mL) and air-dried to obtain the title compound (2.09 g, 100%) as a brown powder. This was used in the next step without further purification. δ H (DMSO-d6,400MHz)7.71-7.91(5H,m),7.93-8.01(2H,m),8.16-8.23(2H,m),8.40(1H ,d,J=8.9Hz),8.92(1H,d,J=8.1Hz),8.96(2H,d,J=7.0Hz) and 9.49(2H,d,J=7.0Hz);δ F (DMSO-d6, 376MHz)-77.75.

[0104] Compound 3: 1-Methyl-2-(1-phenylpyridine-1-ium-4-yl)naphtho[1,2-d]thiazole-1-iumbis(tetrafluoroborate) [ka] A solution of 4-(naphtho[1,2-d]thiazole-2-yl)-1-phenylpyridine-1-ium trifluoromethanesulfonate (2.09 g, 4.3 mmol) in methyl trifluoromethanesulfonate (9.03 g, 55.1 mmol) was heated under reflux. After 2 days, the solution was diluted with Et2O (40 mL), and the residue was collected by filtration. The filtrate was washed with Et2O (2 × 10 mL) and air-dried. The solid was extracted with water (2 × 100 mL), and the solvent was removed under reduced pressure. Next, the residue was dissolved in MeOH (5 mL) and added dropwise to a solution of NaBF4 (5.05 g, 45.9 mmol) in water (40 mL) with stirring. Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (3 × 5 mL), and triturated with hot MeOH (20 mL). After cooling, the residue was filtered off and air-dried to obtain the title compound (0.23 g, 8%) as a pale yellow solid. δ H (DMSO-d6,400MHz)4.74(3H,s),7.76-8.12(7H,m),8.40-8.70(3H,br.m),8.8 2(2H,br.d,J=3.3Hz),9.11(1H,d.dm,J=9.0Hz) and 9.79(2H,br.d,J=3.3Hz);δ F (DMSO-d6, 376MHz) -148.25 and -148.20.

[0105] Example 4 Quinoline-4-carbaldehyde [ka] A mixture of 4-methylquinoline (6.00 g, 41.9 mmol), p-toluenesulfonic acid (7.22 g, 42 mmol), and iodine (4.26 g, 16.8 mmol, 40 mol%) in DMSO (300 mL) was heated at 130 °C for 16 hours, cooled, and added to water (400 mL) for basing (K₂CO₃). The mixture was extracted with ELISA (5 × 100 mL). The combined organic extract was washed with an aqueous solution of Na₂S₂O₃ (300 mL), then with brine (200 mL), and dried (Na₂SO₄). The solvent was removed under reduced pressure, and the title compound (6.11 g, 93%) was obtained as a beige solid. δ H(CDCl3,400MHz) 7.75 (1H,ddd,J=1.4,6.9 and 8.4Hz), 7.80 (1H,d,J=4.3Hz), 7.83 (1H,d,J=1.4,6.9 and 8.4), 8.23 ​​(1H,ddd,J=0.7,1.4 and 8.4Hz), 9.11 (1H,ddd,J=0.7,1.4 and 8.4Hz), 9.21 (1H,d,J=4.3Hz) and 10.53 (1H,s);δ C (CDCl3, 100MHz) 123.89, 124.44, 125.87, 129.42, 130.06, 130.22, 136.76, 149.28, 150.48 and 192.92.

[0106] 2-(quinoline-4-yl)-2,3-dihydrobenzothiazole [ka] A solution of quinoline-4-carbaldehyde (3.00 g, 19.1 mmol) and 2-aminobenzenethiol (2.39 g, 19.1 mmol) in EtOH (40 mL) was stirred under air for 2 days. The solvent was decanted, and the residue was crystallized from hot EtOH (40 mL) and cooled to 0°C. The product was collected by filtration, washed with EtOH (10 mL), and air-dried to obtain the title compound (2.38 g, 47%) as an orange prism. The filtrate was concentrated under reduced pressure to obtain a second crop (1.19 g, 23%) as a yellow powder. δ H (DMSO-d6,400MHz) 6.62 (1H,dt,J=1.2 and 7.5Hz), 6.78 (1H,br.dd,J=1.1 and 7.8Hz), 6.94 (1H,dt,J=1,3 and 7.7Hz), 6.99 (1H,dd,J=1.2 and 7.4Hz), 7.15 (2H,s), 7.62 (1H,d,J=4.5Hz), 7.67 (1H,ddd,J=1.4,6.9 and 8.4Hz), 7.79 (1H,ddd,J=1.4,6.9,8.4Hz), 8.07 (2H,br.t,J=8.8Hz) and 8.88 (1H,d,J=4.4Hz); δ C(DMSO-d6, 100MHz) 64.46, 109.88, 117.60, 119.59, 121.94, 123.84, 124.74, 125.14, 126.21, 127.39, 129.94, 130.26, 148.02, 148.16, 148.40 and 151.08.

[0107] 2-(quinoline-4-yl)benzothiazole [ka] Solid DDQ (1.29 g, 5.7 mmol) was added to a solution of 2-(quinoline-4-yl)-2,3-dihydrobenzothiazole (1.50 g, 5.7 mmol) in DCM (1.2 L). The mixture was stirred at room temperature for 1 hour, and then filtered through silica using siRNA (60% in hexane) as the eluent. The solvent was removed under reduced pressure, and the residue was dissolved in siRNA (200 mL) and washed sequentially with KOH (200 mL, 2 M), water (2 × 100 mL), and brine (100 mL). The extract was dried with (Na₂SO₄) and the solvent was removed under reduced pressure. The residue was crystallized from hot siRNA / hexane. After cooling to -4°C, the product was collected by vacuum filtration and washed with cold hexane to obtain the title compound (1.19 g, 80%) as pale lime-colored needle-shaped particles. δ H (CDCl3, 400MHz) 7.52 (1H,ddd,J=1.3,7.3 and 7.9Hz), 7.60 (1H,ddd,J=1.3,7.2 and 8.2Hz), 7.70 (1H,ddd,J=1.3,6.8 and 8.7Hz), 7.80 (1H,d,J=4.4Hz), 7.82 (1H,ddd,J=1.4,6.9 and 8 0.4Hz), 8.02 (1H,ddd,J=0.7,1.3 and 8.0Hz), 8.22 (1H,ddd,J=0.7,1.4 and 8.4Hz), 8.24 (1H,ddd,J=0.6,1.2 and 8.2Hz), 9.00 (1H,ddd and J=0.7,1.4 and 8.5Hz) and 9.05 (1H,d,J=4.4Hz); δ C(CDCl3,100MHz)121.63,122.19,124.12,124.98,126.04,126.17,126.76 ,128.19,130.00(2×C),135.34,138.32,149.20,149.80,154.18,164.80.

[0108] 4-(benzothiazole-2-yl)-1-phenylquinoline-1-iumtetrafluoroborate [ka] A mixture of 2-(quinoline-4-yl)benzothiazole (1.00 g, 3.8 mmol), diphenyliodonium trifluoromethanesulfonate (2.46 g, 5.7 mmol), and Cu(OAc)2·H2O (76 mg, 10 mol%) in DMF (30 mL) was heated at 100 °C for 16 hours under N2. The resulting solution was cooled, the solvent was removed under reduced pressure, and the residue was triturated with Et2O (3 × 40 mL) to give a mixture of the product and starting materials (62:38). The residue in DMF (30 mL), along with diphenyliodonium trifluoromethanesulfonate (1.64 g, 3.8 mmol) and Cu(OAc)2·H2O (76 mg, 10 mol%), was heated at 100 °C for 16 hours under N2. The resulting solution was cooled, and the solvent was removed under reduced pressure. The residue was tritulated with Et2O (3 × 40 mL) to obtain a mixture of the product and reactants (70:30). This solid was dissolved in warm MeOH (20 mL) and added dropwise to a solution of NaBF4 (8.40 g, 76 mmol) in water (50 mL) with stirring. Stirring was continued for 0.5 hours, and the resulting precipitate was collected by filtration and washed with water (5 mL). This solid was dissolved in hot MeOH (20 mL) and added dropwise to NaBF4 (8.40 g, 76 mmol) in water (50 mL) with stirring. Stirring was continued for 0.5 hours, and the resulting precipitate was filtered off, washed with water (5 mL), and air-dried to obtain a yellow powder. This powder was pulverized with hot EtOH (2 × 5 mL) to obtain the title compound (1.01 g, 54%) as a yellow powder. δ H(CDCl3,400MHz)7.67-7.79(2H,m),7.79-8.92(6H,m),8.12-8.24(2H,m),8.27(1H,br.d,J=7.6Hz),8.3 8(1H,br.d,J=7.9Hz),8.68(1H,d,J=6.2Hz),9.52(1H,d,J=6.2Hz) and 9.69(1H,br.dd,J=1.5 and 8.3Hz);δ F (CDCl3,376MHz)-154.67 and -154.62;δ C (CDCl3, 100MHz) 120.31, 122.03, 122.56, 124.59, 126.34, 126.89, 127.61, 127.76, 128.91, 130.47, 131.13, 131.79, 135.76, 136.23, 140.35, 140.92, 148.20, 149.02, 154.37, and 161.44.

[0109] Compound 4: 3-methyl-2-(1-phenylquinoline-1-ium-4-yl)benzothiazole-3-ium tetrafluoroborate [ka] A mixture of 4-(benzothiazole-2-yl)-1-phenylquinoline-1-ium tetrafluoroborate (1.01 g, 2.4 mmol) in MeOTs (4.61 g, 24.8 mmol) was heated at 180°C for 3 hours, then cooled and triturated with Et2O (3 × 30 mL). The washing solution was discarded, and the residue was dried under N2. The residue was dissolved in hot MeOH (40 mL) and added dropwise to a solution of NaBF4 (4.55 g, 41.4 mmol) in water (40 mL) with stirring. Stirring was continued for 0.5 hours, the precipitate was collected by filtration, washed with water (2 × 5 mL), then washed with hot MeOH (5 mL), and air-dried. The residue was triturated with AcMe (3 mL) to obtain the title compound (0.70 g, 56%) as an off-white powder. δ H[(CD3)2CO, 600MHz] 4.52 (3H,s), 7.88-8.02 (5H,m), 8.07 (1H,app.br.d,J=9.0Hz), 8.12 (1H,ddd,J=0.7,7.3 and 8.7Hz), 8.19-8.24 (2H,m), 8.39 (1H,ddd,J=1.3,7.0 and 9.0Hz), 8.57 (1H,ddd,J=0.6,1.3 and 8.5Hz), 8.64 (1H,ddd,J=0.7,1.6,7.9Hz), 8.75 (1H,ddd,J=0.6,1.2 and 7.3Hz), 9.00 (1H,d,J=5.9Hz) and 9.97 (1H,d,J=5.9Hz);δ F [(CD3)2CO, 470MHz]-151.44 and -151.39;δ C [(CD3)2CO, 125MHz] 38.76, 118.09, 121.40, 124.76, 125.84, 126.59, 127.07, 128.87, 130.00, 130.73, 131.06, 132.25, 132.32, 132.52, 137.16, 140.39, 140.69, 141.56, 142.98, 150.58 and 166.95.

[0110] Example 5 3-(pyridine-4-yl)-1,2-benzisothiazole [ka] nBuLi (2.5 M in hexane) (32.2 mL, 80.5 mmol) was added dropwise under N2 to a stirred solution of thioanisole (2.00 g, 16.1 mmol) and N,N,N',N'-tetramethylethylenediamine (5.60 g, 7.24 mL, 48.3 mmol) in tert-butyl methyl ether (80 mL). The reaction mixture was then stirred under N2 at room temperature for 3 hours. Next, 4-pyridinecarbonile (16.76 g, 161 mmol) was partially added, and the reaction mixture was stirred under N2 at room temperature for 24 hours. The reaction mixture was then carefully quenched with saturated NH4Cl (100 mL) and extracted with DCM (3 × 200 mL). The organic layers were combined, dried (Na2SO4), filtered, and the solvent was removed under reduced pressure. The resulting residue was chromatographed on silica gel [eluent ratio was gradually changed from 1:9 to 4:6 siRNA:DCM]. The solvent from the obtained column fraction was removed under reduced pressure, and the resulting residue was chromatographed again with silica gel [eluent ratio was gradually changed from 1:9 to 4:6 siRNA:DCM]. The solvent from the obtained column fraction was removed under reduced pressure, and the resulting residue was recrystallized from hot petroleum ether and filtered to obtain the title compound (0.33 g, 15%) as colorless, transparent crystals. The recrystallized filtrate was left at -20°C for 16 hours to obtain a second crop as colorless crystals (0.15 g, 7%). Yield and yield: 0.48 g, 22%. δ H (CDCl3,400MHz)8.81(2H,d,J=5.3Hz),8.18(1H,d,J=8.2Hz),8.02(1H,d,J=8 .2Hz),7.79(2H,d,J=5.9Hz),7.59(1H,t,J=7.3Hz) and 7.50(1H,t,J=7.3Hz);δ C (CDCl3, 100MHz) 161.4, 153.9, 150.5, 142.2, 133.36, 127.9, 125.6, 124.1, 123.0 and 120.2.

[0111] Compound 5: 4-(1,2-benzisothiazol-3-yl)-1-phenylpyridine-1-iumtetrafluoroborate [ka] 3-(pyridine-4-yl)-1,2-benzisothiazole (0.36 g, 1.7 mmol), diphenyliodonium trifluoromethanesulfonate (1.12 g, 2.6 mol), and Cu(OAc)2·H2O (34 mg, 0.17 mmol) were dissolved in DMF (20 mL) under N2, and the reaction mixture was stirred at 100°C for 16 hours. The reaction mixture was cooled to room temperature, and the solvent was removed under reduced pressure. The resulting pale yellow solid was triturated with diethyl ether (3 × 50 mL), filtered, and dried under reduced pressure. The resulting pale yellow solid was dissolved in hot MeOH (150 mL) and added dropwise through a cotton plug to a stirred solution of NaBF4 (15.0 g) in H2O (300 mL), forming a pale yellow precipitate. This suspension was stirred for 30 minutes and then filtered under reduced pressure. The obtained solid was washed with water (30 mL) and dried under reduced pressure to obtain a pale yellow powder. This solid was dissolved in hot acetone and added dropwise through a cotton plug to the filtrate (which had decreased by approximately 30% under vacuum), yielding a pale yellow precipitate. The resulting suspension was filtered under reduced pressure, and the obtained solid was washed with water (30 mL) and dried under reduced pressure to obtain the title compound as a pale yellow powder. Yield: 0.38 g, 59%. δ H (DMSO-d6,400MHz)9.55(2H,d,J=6.9Hz),8.84(2H,d,J=6.9Hz),8.52(2H,d,J=8.9Hz),8.07-7.95(2H,m) and 7.92-7.71(5H,m);δ C (DMSO-d6, 100MHz) 157.4, 154.0, 148.8, 145.6, 142.5, 132.8, 131.4, 130.3, 128.6, 126.8, 126.6, 124.8, 123.9 and 121.5; δ F (DMSO-d6,376MHz)-148.22(4F,br.m).

[0112] Example 6 Compound 6: 2-methyl-3-(1-phenylpyridine-1-ium-4-yl)-1,2-benzisothiazole-2-iumbis(hexafluorophosphate) [ka] 4-(1,2-benzisothiazol-3-yl)-1-phenylpyridine-1-ium tetrafluoroborate (0.30 g, 0.8 mmol) was suspended in trifluoromethanesulfonate (0.8 g, 5.4 mmol), and the reaction mixture was stirred under N2 at 100°C for 80 minutes. Next, the reaction mixture was stirred under N2 at 40°C for 4 hours. After cooling to room temperature, diethyl ether (50 mL) was added, and the resulting suspension was filtered to obtain a brown powder. This was triturated with ether (3 × 50 mL) and dried under reduced pressure. This brown powder was dissolved in hot MeOH (50 mL) and added dropwise through a cotton plug to a stirred solution of NH4PF6 (10.0 g) in H2O (200 mL), forming a brown precipitate. Next, the precipitate was washed with water (30 mL) and dried under reduced pressure to obtain a light brown powder. Next, the title compound was obtained as a light brown powder by recrystallizing this light brown powder from hot MeOH. Yield: 0.18 g, 38%. δ H (DMSO-d6,400MHz)9.81(2H,d,J=6.9Hz),8.75(2H,d,J=6.9Hz),8.71(1H,d,J=6.6Hz),8. 18(1H,ddd,J=8.5,7.3,0.9Hz),8.10(1H,d,J=6.6Hz),8.05-7.82(6H,m) and 4.33(3H,s);δ C (DMSO-d6, 100MHz) 159.3, 147.8, 146.2, 142.5, 142.4, 134.5, 131.9, 130.9, 130.5, 129.3, 128.8, 127.0, 124.7, 122.9 and 39.5; δ F (DMSO-d6,376MHz)-70.14(12F,d,J=711.5Hz).

[0113] 2. (Benz)imidazole and condensed cyclic derivatives Example 7 2-(pyridine-4-yl)-1H-benzimidazole [ka] A solution of o-phenylenediamine (10.10 g, 93.5 mmol) and pyridine-4-carboxyaldehyde (10.00 g, 93.5 mmol) in EtOH (500 mL) was stirred under air for 72 hours, and the solvent was removed under reduced pressure. After crystallization of the residue from siRNA / hexane, the title compound (11.44 g, 63%) was obtained as a brown powder by triple trituration with hot siRNA. δ H (DMSO-d6,400MHz)7.26(2H,bs),7.59(1H,vbs),7.71(1H,vbs),8.80(2H,d,J=6.1Hz),8.75(2H,d,J=6.1Hz) and 13.26(1H,bs).

[0114] 1-Methyl-2-(pyridine-4-yl)-1H-benzimidazole [ka] A mixture of 2-(pyridine-4-yl)-1H-benzimidazole (5.33 g, 27.3 mmol), MeI (5.33 mL, 12.15 g, 85.6 mmol), and KOH (7.83 g, 140 mmol) in acetone (660 mL) was stirred at room temperature for 2 hours and then added to PhMe (700 mL). The resulting solution was washed with water (1 L) and brine (100 mL), dried, and the solvent was removed under reduced pressure using (Na2SO4). The residue was filtered through neutral alumina using siRNA as the eluent. The solvent was removed under reduced pressure, and the residue was crystallized from siRNA / hexane to obtain the title compound (2.80 g, 49%) as a yellow plate-like material. δ H (CDCl3,400MHz)3.83(3H,s),7.72-7.46(3H,m),7.72(2H,d,J=6.0Hz),7.83-7.87(1H,m) and 8.06(2H,d,J=6.0Hz);δ C (CDCl3, 100MHz) 31.84, 109.88, 120.37, 123.03, 123.45, 123.74, 136.74, 137.86, 142.91, 150.38, and 150.76.

[0115] 1-Hexyl-4-(1-methyl-1H-benzimidazole-2-yl)pyridine-1-iumtetrafluoroborate [ka] A solution of 1-methyl-2-(pyridine-4-yl)-1H-benzimidazole (1.47 g, 7 mmol) and 1-iodohexane (4.47 g, 21.1 mmol) in MeCN (40 mL) was heated under gas circulation with stirring in the dark under N2. After 24 hours, the resulting mixture was cooled, diluted with Et2O (60 mL), filtered, washed with Et2O (30 mL), and dried under vacuum. The hygroscopic orange powder was dissolved in MeOH (30 mL) and added dropwise to a solution of NaBF4 (4.55 g, 41.4 mmol) in water (200 mL) with stirring. Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (3 × 10 mL), and air-dried to obtain the title compound (1.91 g, 73%) as a pale yellow powder. δ H [(CD3)2CO,400MHz]0.88(3H,t,J=7.3Hz),1.27-1.56(6H,m),2.15-2.27(2H,m),4.23(3H,s),4.93(2H,t,J=7.7Hz),7.39(1H,ddd,J=1.1, 7.1 and 8.2Hz), 7.48(1H,ddd,J=1.2,7.1 and 8.2Hz),7.70-7.74(1H,m),7.80-7.84(1H,m),8.80(2H,d,J=6.9Hz) and 9.34(2H,d,J=6.9HzHz);δ F [(CD3)2CO, 376MHz]-151.70 and -151.54;δ C [(CD3)2CO, 100MHz] 13.31, 22.17, 25.54, 31.00, 31.24, 32.08, 61.60, 111.15, 120.61, 123.44, 125.00, 127.04, 137.95, 143.21, 145.02, 145.87 and 147.05.

[0116] Compound 7: 2-(1-hexylpyridine-1-ium-4-yl)-1,3-dimethyl-1H-benzimidazole-3-iumbis(tetrafluoroborate) [ka] A mixture of 1-hexyl-4-(1-methyl-1H-benzimidazole-2-yl)pyridine-1-ium tetrafluoroborate (0.50 g, 1.3 mmol) in MeOTs (4.00 g, 21.5 mmol) was heated at 180°C for 90 minutes, cooled, and then triturated with Et2O (3 × 30 mL). The residue was dissolved in MeOH (20 mL) and added dropwise to a solution of NaBF4 (20.97 g, 190 mmol) in water (100 mL) with stirring. Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (2 × 3 mL), and air-dried to obtain 2-(1-hexylpyridine-1-ium-4-yl)-1,3-dimethyl-1H-benzimidazole-3-ium bis(tetrafluoroborate) (0.45 g, 71%) as a gray powder. δ H (CD3OD,400MHz)0.91-0.99(3H,m),1.35-1.59(6H,m),2.10-2.22(2H,m),4.07(6H,s),4.81(2H,t ,J=7.6Hz),7.81-7.88(2H,m),8.05-8.12(2H,m),8.61(2H,d,J=5.4Hz) and 9.43(2H,d,J=5.4Hz);δ F (DMSO-d6,376MHz)-148.25;δ C (DMSO-d6, 100MHz) 14.34, 22.34, 25.60, 31.14, 31.37, 33.44, 62.15, 114.19, 128.06, 130.84, 132.49, 136.91, 145.57 and 146.60.

[0117] Example 8 Compound 8: 2-(1-hexylpyridine-1-ium-4-yl)-1,3-dimethyl-1H-benzimidazole-3-iumbis(hexafluorophosphate) [ka] Solid ammonium hexafluorophosphate (1.16 g, 7.1 mmol) was added to the aqueous filtrate and washing solution obtained during the preparation of compound 3. The resulting precipitate was filtered, washed with water (2 × 2 mL), triturated with hot MeOH (2 mL), and air-dried to obtain 2-(1-hexylpyridine-1-ium-4-yl)-1,3-dimethyl-1H-benzimidazole-3-iumbis(hexafluorophosphate) (0.21 g, 27%) as a creamy powder. δ H (DMSO-d6,400MHz)0.89(3H,t,J=6.8Hz),1.25-1.47(6H,m),1.94-2.08(2H,m),3.97(6H,s),4. 74(2H,m),7.81-7.88(2H,m),8.15-8.23(2H,m),8.63(2H,d,J=6.4Hz) and 9.48(2H,d,J=6.4Hz);δ F (DMSO-d6,376MHz)-70.13(d,J=710Hz);δ C (DMSO-d6, 100MHz) 14.34, 22.35, 25.60, 31.14, 31.40, 33.47, 62.14, 114.20, 128.09, 130.87, 132.48, 136.90, 145.57 and 146.61.

[0118] Example 9 1-Hexyl-2-(pyridine-4-yl)-1H-benzimidazole [ka] A mixture of 2-(pyridine-4-yl)-1H-benzimidazole (2.00 g, 10.3 mmol), powdered KOH (0.92 g, 16.4 mmol), and 1-iodohexane (2.39 g, 11.3 mmol) in anhydrous DMSO (30 mL) was stirred at room temperature under N2 for 24 hours. The mixture was then added to water (100 mL) and extracted with DCM (3 × 100 mL). The combined extract was washed with water (100 mL), dried, and the solvent was removed under reduced pressure (Na₂SO₄). The residue was filtered through silica using siRNA as the eluent. The solvent was removed under reduced pressure, the residue was triturated with hexane (3 × 50 mL), filtered, washed with hexane, and air-dried to obtain the title compound (2.53 g, 91%) as a yellowish-brown powder. δ H (CDCl3,400MHz)0.77-0.87(3H,m),1.17-1.35(6H,m),1.83-1.96(2H,m),4.450(2H,t,J =7.6),7.47-7.66(3H,m),7.90(2H,d,J=6Hz),7.94(1H,d,J=8Hz) and 8.93(2H,d,J=6Hz);δ C (CDCl3, 100MHz) 13.85, 22.36, 26.26, 29.70, 30.99, 46.00, 111.72, 118.10, 124.02, 126.43, 126.58, 133.56, 134.98, 135.17, 147.07, and 149.00.

[0119] Compound 9: 3-Hexyl-1-methyl-2-(1-methylpyridine-1-ium-4-yl)-1H-benzimidazole-3-iumbis(hexafluorophosphate) [ka] A mixture of 1-hexyl-2-(pyridine-4-yl)-1H-benzimidazole (0.51 g, 1.84 mmol) in MeOTs (1.71 g, 9.2 mmol) was heated at 180°C for 3 hours, cooled, and tritulated with Et2O (3 × 40 mL). The residue was air-dried. The residue was dissolved in MeOH (8 mL) and added dropwise to a solution of NaBF4 (8.10 g, 73.6 mmol) in water (100 mL) with stirring. Stirring was continued for 0.5 hours. Ammonium hexafluorophosphate (10 g, 61 mmol) was added, and stirring was continued for 0.5 hours. The resulting precipitate was filtered, washed with water (2 × 10 mL), tritulated with hot MeOH (40 mL), cooled, filtered, washed with MeOH (5 mL), and air-dried to obtain the title compound as a colorless powder. δ H [(CD3)2CO,400MHz]0.83(3H,t,J=6.7),1.17-1.45(6H,m),1.93-2.02(2H,m),4.17(3H,s),4.63(2H,t, δ F [(CD3)2CO,376MHz]-72.687(d,J=710Hz);δ C [(CD3)2CO, 100MHz] 13.20, 22.19, 25.80, 29.44, 31.07, 32.82, 47.06, 49.33, 99.81, 113.72, 113.86, 128.01, 130.43, 131.81, 132.86, 137.48, 145.90 and 147.99.

[0120] Example 10 4-(1-methyl-1H-benzimidazole-2-yl)-1-phenylpyridine-1-ium triflat [ka] A mixture of 1-methyl-2-(pyridine-4-yl)-1H-benzimidazole (1.00 g, 4.8 mmol), diphenyliodonium triflate (3.08 g, 7.2 mmol), and Cu(OAc)2·H2O (9.6 mg, 0.48 mmol, 10 mol%) in dry DMF (50 mL) was heated at 100 °C for 16 hours, cooled, and the solvent was removed under reduced pressure. The residue was triturated with Et2O (100 mL), air-dried, and then crystallized from hot MeOH (10 mL). The product was isolated by filtration, washed with MeOH, and air-dried to obtain the title compound (1.33 g, 64%) as a yellow powder. δ H [(CD3)2CO,400MHz]4.294(3H,s),7.38-7.45(1H,m),7.47-7.53(1H,m),7. 71-7.90(5H,m),8.01-8.11(2H,m),8.95(2H,d,7Hz) and 9.51(2H,d,J=7Hz);δ F [(CD3)2CO,376MHz]-78.86;δ C [(CD3)2CO, 100MHz] 32.21, 111.26, 120.77, 123.65, 124.62, 125.32, 127.03, 130.60, 131.68, 138.12, 142.98, 143.39, 144.99, 146.72 and 146.88.

[0121] Compound 10: 1,3-dimethyl-2-(1-phenylpyridine-1-ium-4-yl)-1H-benzimidazole-3-iumbis(tetrafluoroborate) [ka] A mixture of 4-(1-methyl-1H-benzimidazole-2-yl)-1-phenylpyridine-1-ium triflate (0.54 g, 1.2 mmol) in MeOTs (4.62 g, 24.8 mmol) was heated at 180°C for 3 hours, cooled, tritulated with Et2O (50 mL), the residue was filtered, washed with Et2O (2 × 10 mL), and air-dried. The residue was dissolved in MeOH (10 mL) and added dropwise to a solution of NaBF4 (2.73 g, 24.8 mmol) in water (50 mL) with stirring. Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (2 × 5 mL), and air-dried. The residue was tritulated with hot MeOH (5 mL), filtered, and air-dried to obtain the title compound (0.49 g, 83%) as a light brown powder. δ H (DMSO-d6,400MHz)4.04(6H,s),7.80-8.01(7H,m),8.19-8.29(2H,m),8.81(2H,d,J=6.5Hz) and 9.82(2H,d,J=6.5Hz);δ F (DMSO-d6,376MHz)-148.26,-148.20;δ C (DMSO-d6, 100MHz) 33.49, 114.25, 125.24, 128.15, 130.84, 130.99, 132.41, 132.53, 137.83, 142.96, 145.50 and 146.81.

[0122] Example 11 Compound 11: 1-Hexyl-3-methyl-2-(1-phenylpyridine-1-ium-4-yl)-1H-benzimidazole-3-iumbis(hexafluorophosphate) [ka] A mixture of 1-hexyl-2-(pyridine-4-yl)-1H-benzimidazole (0.8.0 g, 2.9 mmol), diphenyliodonium triflate (1.85 g, 4.3 mmol), and Cu(OAc)2·H2O (58 mg, 0.29 mmol, 10 mol%) in dry DMF (30 mL) was heated at 100 °C for 16 hours, cooled, and the solvent was removed under reduced pressure. The residue was tritulated with Et2O (3 × 30 mL) and dried under vacuum. The residue was heated in MeOTs (4.26 g, 22.4 mmol) at 180 °C for 2 hours, cooled, and diluted with Et2O (80 mL). The solvent was decanted, the residue was tritulated with Et2O (3 × 30 mL), and dried under vacuum. The residue was dissolved in MeOH (20 mL) and added dropwise to a solution of ammonium hexafluorophosphate (4.16 g, 28.7 mmol) in water (100 mL). The precipitate was filtered, washed with water (2 × 10 mL), and air-dried to obtain the title compound (0.68 g, 38%) as a cream-colored powder. δ H [(CD3)2CO,400MHz]0.82(3H,t,J=6.9Hz),1.17-1.45(6H,m),1.96-2.04(2H,m),4.19(3H,s),4.66(2H,t,J=7.7 Hz),7.81-7.95(5H,m),7.99-8.10(2H,m),8.17-8.32(2H,m),9.13(2H,bd,J=5.2Hz) and 9.89(2H,bd,J=5.2Hz);δ F [(CD3)2CO,376MHz]-72.47(d,J=710Hz);δ C [(CD3)2CO, 100MHz] 13.31, 22.18, 25.82, 29.49, 31.06, 32.92, 47.14, 113.76, 113.94, 124.76, 128.08, 130.75, 130.95, 131.89, 132.35, 132.96, 138.59, 143.02, 144.71 and 147.04.

[0123] 3. Imidazo[1,2-a]pyridines Example 12 7-Bromo-2-phenylimidazo[1,2-a]pyridine A [ka] A mixture of phenacyl bromide (4.00 g, 20.1 mmol), 4-bromopyridine-2-amine (2.90 g, 16.8 mmol), and NaHCO3 (1.69 g, 20.1 mmol) in MeOH (80 mL) was heated under reflux for 5 hours, then cooled to reduce the solvent volume. Water (200 mL) was added, and the resulting mixture was extracted with DCM (3 × 100 mL), dried (Na2SO4), and the solvent was removed under reduced pressure. The residue was chromatographed with silica using MeOH (5% in DCM) as the eluent. The solvent was removed under reduced pressure, and the residue was crystallized from DCM / hexane to obtain the title compound (2.07 g, 39%) as a cream-colored powder. δ H (CDCl3,400MHz)6.91(1H,dd,J=1.9 and 7.1Hz),7.34-7.40(1H,m),7.43-7.49( 2H,m),7.83-7.87(2H,m),7.92-7.98(2H,m) and 8.00(2H,dd,J=0.5 and 7.1Hz);δ C (CDCl3, 100MHz) 108.27, 116.34, 118.21, 119.80, 125.72, 126.12, 128.30, 128.80, 133.27, 145.83, and 146.71.

[0124] 2-phenyl-7-(pyridine-4-yl)imidazo[1,2-a]pyridine C [ka] A mixture of 7-bromo-2-phenylimidazo[1,2-a]pyridine A (1.18 g, 4.3 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.32 g, 6.4 mmol), K2CO3 (0.90 g, 6.5 mmol), and Pd(PPh3)4 (0.20 g, 4 mol%) in degassed PhMe (40 mL) and EtOH (40 mL) was heated under N2 reflux for 16 hours, cooled, added to water (50 mL), and extracted with DCM (3 × 40 mL). The combined extract was dried (Na2SO4) and the solvent was removed under reduced pressure. The residue was chromatographed with silica using MeOH (5% in DCM) as the eluent. The band with Rf=0.5 was collected, the solvent was removed, and the residue was triturated with thermal PhMe (15 mL). After cooling, the product was collected and air-dried to obtain the title compound (1.02 g, 87%) as a cream-colored powder. δ H (CDCl3,400MHz) 7.12 (1H,dd,J=1.6 and 7Hz), 7.35-7.42 (1H,m), 7.45-7.52 (2H,m), 7.59 (2H,dd,J=1.5 and 4.6Hz), 7.94-8.03 (4H,m), 8.25 (1H,dd,J=0.9 and 7Hz) and 8.74 (2H,dd,J=1.4 and 4.7Hz); δ C (CDCl3, 100MHz) 108.43, 111.29, 115.22, 120.96, 125.90, 126.12, 128.34, 128.83, 133.42, 134.26, 145.67, 145.87, 147.38, and 150.66.

[0125] 1-Hexyl-4-(2-phenylimidazo[1,2-a]pyridine-7-yl)pyridine-1-ium iodide F [ka] A mixture of 2-phenyl-7-(pyridine-4-yl)imidazo[1,2-a]pyridine C (1.02 g, 3.8 mmol) and 1-iodohexane (2.39 g, 11.3 mmol) in MeCN (40 mL) was heated under reflux for 16 hours, cooled, the solvent volume was reduced, and the mixture was diluted with Et2O (50 mL). The precipitate was filtered, washed with Et2O (2 × 30 mL), and air-dried to obtain the title compound (1.81 g, 99%) as an orange powder. δ H (CD3OD,400MHz)0.94(3H,t,J=6.9Hz),1.32-1.51(6H,m),2.00-2.14(2H,m),4.63(2H,t,J=7.4Hz),7.37-7.57(4H,m), 7.99(2H,d,J=7.9Hz),8.29(1H,s),8.43(1H,s),8.53(2H,d,J=6.3Hz),8.68(1H,d,J=7.1Hz) and 9.01(2H,d,J=6.3Hz);δ C (CD3OD, 100MHz) 12.85, 22.08, 25.50, 30.91, 30.98, 60.92, 110.62, 110.81, 116.23, 124.51, 125.89, 127.48, 128.49, 128.61, 130.34, 132.67, 144.53 and 153.97

[0126] 1-Hexyl-4-(2-phenylimidazo[1,2-a]pyridine-7-yl)pyridine-1-iumtetrafluoroborate [ka] A solution of 1-hexyl-4-(2-phenylimidazo[1,2-a]pyridine-7-yl)pyridine-1-ium iodide F (1.81 g, 3.7 mmol) in MeOH (20 mL) was added dropwise to a solution of NaBF4 (2.47 g, 22.4 mmol) in water (100 mL) with stirring. Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (5 mL), and air-dried to obtain the title compound (1.66 g, 100%) as a golden powder. This powder was used in the next step without further purification.

[0127] Compound 12: 7-(1-hexylpyridine-1-ium-4-yl)-1-methyl-2-phenylimidazo[1,2-a]pyridine-1-iumbis(tetrafluoroborate) [ka] A mixture of 1-hexyl-4-(2-phenylimidazo[1,2-a]pyridine-7-yl)pyridine-1-ium tetrafluoroborate (1.66 g, 3.7 mmol) and MeOTs (2.79 g, 15 mmol) was heated at 180°C for 2 hours, cooled, triturated with Et2O (3 × 50 mL), and air-dried. The residue was dissolved in MeOH (25 mL) and added dropwise to a solution of NaBF4 (16.48 g, 150 mmol) with stirring. The resulting precipitate was filtered, washed with water (5 mL), dissolved in warm MeOH (50 mL), and added dropwise to a solution of NaBF4 (16.48 g, 150 mmol) in water (250 mL) with stirring. Stirring was continued for 0.5 hours, and the resulting precipitate was filtered. The residue was tritulated with EtOH (3 ml), filtered, and air-dried to obtain the title compound (0.38 g, 19%) as a pale green powder. Ethanol solution was added dropwise to a solution of NaBF4 (16.48 g, 150 mmol) in water (50 mL) with stirring. The resulting precipitate was filtered, washed with water (10 mL), and air-dried to obtain a second crop (0.45 g, 22%) as a khaki-colored powder. δ H [(CD3)2CO,400MHz]0.88(3H,t,J=6.8Hz),1.26-1.55(6H,m),2.12-2.27(2H,m),4.26(3H,s),4.91(2H,t,J=7.2Hz),7.70(3H,bs),7.82 (2H,bs),8.26(1H,bs,J=6.6Hz),8.69(1H,bs),8.86(2H,bd,J=5.8Hz),9.05(1H,bs),9.21(1H,bd,J=6.6Hz) and 9.34(2H,bd,J=5.8Hz);δ F (CDCl3,376MHz)-151.02,-150.97;δ C(CDCl3, 100MHz) 13.31, 22.16, 25.54, 30.98, 31.26, 32.42, 61.73, 111.65, 113.97, 116.12, 125.24, 126.39, 129.44, 130.01, 130.29, 131.13, 138.32, 140.23, 140.38, 145.62, and 151.68.

[0128] Example 13 7-Bromo-2-(pyridine-4-yl)imidazo[1,2-a]pyridine B [ka] A mixture of 4-(bromoacetyl)pyridine hydrobromide (8.00 g, 28.5 mmol), 4-bromopyridine-2-amine (4.1 g, 23.7 mmol), and NaHCO3 (4.78 g, 56.9 mmol) in MeOH (80 mL) was heated under reflux for 5 hours, cooled, and the solvent volume was reduced. Water (200 mL) was added, and the resulting mixture was extracted with DCM (3 × 150 mL), dried (Na2SO4), and the solvent was removed under reduced pressure. The residue was chromatographed with silica using MeOH (5% in DCM) as the eluent. The fluorescence band with Rf = 0.6 (5% MeOH in DCM) was recovered. The solvent was removed under reduced pressure, and the residue was crystallized from MeOH (5 mL) at 3°C, filtered, and air-dried to obtain the title compound (0.68 g, 10%) as a light brown powder. δ H (CDCl3,400MHz) 6.96 (1H,dd,J=1.7 and 7.2Hz), 7.82 (2H,d,J=6Hz), 7.86 (1H,bs), 8.00 (1H,bs), 8.04 (1H,d,J=7.2Hz) and 8.69 (2H,d,J=6Hz); δ C (CDCl3, 100MHz) 110.02, 117.09, 119.21, 120.19, 120.33, 125.95, 140.69, 143.88, 146.07 and 150.40.

[0129] 7-phenyl-2-(pyridine-4-yl)imidazo[1,2-a]pyridine D [ka] A mixture of 7-bromo-2-(pyridine-4-yl)imidazo[1,2-a]pyridine B (1.17 g, 4.3 mmol), phenylboronic acid (0.78 g, 6.4 mmol), K2CO3 (0.88 g, 6.4 mmol), and Pd(PPh3)4 (0.25 g, 5 mol%) was heated under reflux under N2 for 24 hours in degassed PhMe (30 mL) and EtOH (30 mL), cooled, added to water (100 mL), and extracted with DCM (3 × 80 mL). The extract was dried (Na2SO4) and the solvent was removed under reduced pressure. The residue was chromatographed with silica using MeOH (5% in DCM) as the eluent. The solvent was removed under reduced pressure, and the residue was triturated with hexane containing a few drops of DCM. The residue was filtered, washed with hexane, and air-dried to obtain the title compound (1.02 g, 88%) as a light brown powder. δ H (CDCl3,400MHz)7.16(1H,dd,J=1.6 and 7Hz),7.41-7.57(2H,m),7.66-7.72(2H, m),7.83-7.92(3H,m),8.03(1H,s),8.21(1H,d,J=7Hz) and 8.70(2H,d,J=6Hz);δ C (CDCl3, 100MHz) 109.55, 113.14, 114.54, 120.29, 125.66, 126.74, 128.53, 129.19, 138.40, 138.57, 141.16, 143.81, 146.49 and 150.37.

[0130] 1-Hexyl-4-(7-phenylimidazo[1,2-a]pyridine-2-yl)pyridine-1-ium iodide G [ka] A mixture of 7-phenyl-2-(pyridine-4-yl)imidazo[1,2-a]pyridine D (1.00 g, 3.7 mmol) and 1-iodohexane (2.62 g, 12.4 mmol) in MeCN (40 mL) was heated under reflux for 16 hours, cooled, diluted with Et2O (100 mL), and stirred for 0.5 hours. The resulting precipitate was filtered, washed with Et2O (3 × 40 mL), and air-dried to obtain the title compound (1.73 g, 97%) as a dull yellow powder. δ H (CD3OD,400MHz)0.95(3H,t,J=6.8Hz),1.32-1.54(6H,m),2.00-2.13(2H,m),4.61(2H,t,J=7.3Hz),7.40-7.59(4H,m) ),7.81(2H,d,J=7.6Hz),7.87(1H,s),8.56(2H,d,J=6Hz),8.61(1H,d,J=7.2Hz),8.87(1H,s) and 8.96(2H,d,J=6Hz);δ C (CD3OD, 100MHz) 12.85, 22.07, 25.49, 30.90, 60.82, 112.96, 114.05, 115.63, 123.02, 126.49, 127.25, 128.74, 128.94, 137.62, 138.98, 140.88, 144.41, 147.30, and 149.56.

[0131] Compound 13: 2-(1-hexylpyridine-1-ium-4-yl)-1-methyl-7-phenylimidazo[1,2-a]pyridine-1-iumbis(tetrafluoroborate) [ka] A solution of 1-hexyl-4-(7-phenylimidazo[1,2-a]pyridine-2-yl)pyridine-1-ium iodide G (1.73 g, 3.8 mmol) in MeOH (50 mL) was added dropwise to NaBF4 (10.00 g, 90 mmol) water (100 mL) with stirring, while filtering through a cotton swab plug. Stirring was continued for 0.5 hours, and the resulting precipitate was collected by filtration, washed with water (2 × 5 mL), and air-dried. The resulting solid and MeOTs (2.87 g, 15.4 mmol) were heated at 180 °C with stirring for 2 hours. The resulting oily liquid was cooled, triturated with Et2O (5 × 50 mL), and air-dried. The resulting gummy solid was dissolved in MeOH (30 mL) and added dropwise to a solution of NaBF4 (7.54 g, 68.5 mmol) in water (100 mL) while stirring. Stirring continued for 0.5 hours, the resulting precipitate was collected, dissolved in hot MeOH (60 mL), and added dropwise to NaBF4 (7.54 g, 68.5 mmol) in water (100 mL) while stirring. Stirring continued for 0.5 hours, the resulting precipitate was filtered, washed with water (2 × 10 mL), and air-dried. The title compound (1.37 g, 74%) was obtained as a brown powder by crystallizing the solid from hot MeOH (30 mL), filtering, and air-drying. δ H [(CD3)2CO,400MHz]0.90(3H,t,J=7Hz),1.29-1.59(6H,m),2.16-2.28(2H,m),4.41(3H,s),4.96(2H,t,J=7.5Hz),7.59-7.6 9(3H,m),8.02-8.16(3H,m),8.65(1H,bs),8.70(2H,d,J=6.2Hz),9.02(1H,bs),9.12(1H,d,J=7Hz) and 9.41(2H,d,J=6.2Hz);δ F [(CD3)2CO,376MHz]-151.24,-151.18;δ C [(CD3)2CO, 100MHz] 13.29, 22.14, 25.54, 30.98, 31.25, 32.80, 62.15, 107.70, 116.81, 117.43, 127.72, 128.36, 129.55, 130.05, 130.73, 133.24, 135.84, 142.18, 142.50, 145.77 and 147.56.

[0132] Example 14 2,7-di(pyridine-4-yl)imidazo[1,2-a]pyridine E [ka] A mixture of 7-bromo-2-(pyridine-4-yl)imidazo[1,2-a]pyridine B (1.25 g, 4.6 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.22 g, 5.9 mmol), K2CO3 (0.82 g, 5.9 mmol), and Pd(PPh3)4 (0.26 g, 5 mol%) in degassed PhMe (30 mL) and EtOH (30 mL) was heated under N2 reflux for 16 hours, cooled, and the solvent was removed under reduced pressure. The residue was washed with water (3 × 50 mL) and air-dried. The residue was chromatographed on silica (pre-treated with Et3N (10% in DCM)) using eluents obtained by progressively changing the mixture from Et3 (10% in DCM) to Et3N / MeOH / DCM (12 / 3 / 85). The solvent was removed from the fraction under reduced pressure, and the residue was tritulated with hexane. The resulting solid was dissolved in MeOH (10 mL) and water (100 mL) was added. The resulting precipitate was filtered, washed with water, and air-dried to obtain a yellow powder. This powder was used in the next step without purification. δ H (CD3OD,400MHz)7.38(1H,dd,J=1.7 and 7.2Hz),7.84(2H,d,J=6.3Hz),7.96(2H,d,J =6.2Hz),7.98(1H,bs),8.51(1H,bs),8.54-8.62(2H,m) and 8.65(2H,d,J=6.2Hz);δ C (CD3OD, 100MHz) 111.88, 111.99, 114.05, 120.46, 121.38, 127.36, 135.64, 141.74, 142.94, 145.89, 146.28, 149.28, and 149.58.

[0133] 4,4'-(imidazo[1,2-a]pyridine-2,7-diyl)bis(1-hexylpyridine-1-ium)bis(tetrafluoroborate)H [ka] A solution of 2,7-di(pyridine-4-yl)imidazo[1,2-a]pyridine E (0.80 g, 2.9 mmol) and 1-iodohexane (3.74 g, 17.6 mmol) in MeCN (50 mL) was heated under reflux for 16 hours, cooled, and the solvent was reduced in volume (approximately 20 mL) before adding Et2O (60 mL). The resulting precipitate was filtered, washed with Et2O (2 × 30 mL), and air-dried to obtain 1.69 g. The yellow powder dissolved in MeOH (60 mL) was filtered through a cotton plug and added dropwise to NaBF4 (6.47 g, 58.8 mmol) in water (300 mL) with stirring. The resulting precipitate was filtered, washed with ice-cold water (2 × 20 mL), and air-dried to obtain the title compound (1.32 g, 72%) as a green fluorescent powder. δ H (DMSO-d6,400MHz)0.83-0.94(6H,m),1.24-1.39(12H,m),1.90-2.03(4H,m),4.54-4.65(4H,m),7.75(1H,dd,J=1. 4 and 7.3Hz), 8.62-8.76(5H,m),8.93(2H,d,J=7.2Hz),9.10(2H,d,J=6.7Hz),9.16(1H,bs) and 9.20(2H,d,J=6.7Hz);δ F (DMSO-d6,376MHz)-148.21,-148.16;δ C (DMSO-d6, 100MHz) 14.31, 14.32, 22.34, 22.35, 25.57, 25.59, 31.02, 31.07, 31.10, 60.57, 60.61, 112.43, 117.54, 118.58, 123.59, 125.09, 129.20, 132.08, 141.17, 145.40, 145.51, 145.89, 148.60 and 152.42.

[0134] Compound 14: 4,4'-(1-methylimidazo[1,2-a]pyridine-1-ium-2,7-diyl)bis(1-hexylpyridine-1-ium)tris(tetrafluoroborate) [ka] A mixture of 4,4'-(imidazo[1,2-a]pyridine-2,7-diyl)bis(1-hexylpyridine-1-ium)bis(tetrafluoroborate) (1.17 g, 1.9 mmol) and MeOTs (2.83 g, 15.2 mmol) was heated at 180 °C for 2 hours, cooled, and triturated with Et₂O (50 mL). The residue was filtered and dried under vacuum to obtain 1.85 g. This solid was dissolved in MeOH (30 mL) and added dropwise with stirring to a solution of NaBF₄ (30 g, 270 mmol) in water (250 mL). Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (2 × 5 mL), and air-dried. The residue was dissolved in MeOH / H₂O (30 mL, 1:1) and added dropwise with stirring to NaBF₄ (20 g, 182 mmol) in water (150 mL). The mixture was stirred for 0.5 hours, the resulting precipitate was filtered, washed with water (2 × 5 mL), and air-dried to obtain the title compound (0.99 g, 73%) as a gray powder. δ H [(CD3)2CO,400MHz]0.84-0.96(6H,m),1.27-1.59(12H,m),2.16-2.28(4H,m),4.42(3H,s),4.91-5.04(4H,m),8.33(1H,bd,J=6.7Hz ),8.73(2H,bd,J=6Hz),8.90(2H,bd,J=6Hz),8.12(2H,app.bs),9.29(1H,bd,J=7Hz),8.40(2H,bd,J=6.4Hz) and 9.45(2H,bd,J=6Hz);δ F [(CD3)2CO,376MHz]-151.17,-151.12;δ C [(CD3)2CO, 100MHz] 13.29, 22.14, 25.54, 30.98, 31.25, 31.28, 33.13, 61.85, 62.27, 111.97, 116.76, 117.63, 126.64, 128.75, 130.89, 134.01, 140.01, 141.69, 141.84, 145.70, 145.85 and 151.48.

[0135] 4. Phenanthroimidazoles Example 15 6,9-Dibromo-1,2-bis[4-(tert-butyl)phenyl]-1H-phenanthro[9,10-d]imidazole [ka] To a stirred mixture of 4-tert-butylaniline (2.20 g, 14.6 mmol, 2.35 mL, 1.5 equivalents) and 4-tert-butylbenzaldehyde (1.58 g, 9.75 mmol, 1.53 mL), acetic acid (100 mL) was added, followed by 3,6-dibromophenanthrene-9,10-dione (3.58 g, 9.75 mmol) and ammonium acetate (9.38 g, 122 mmol, 12.5 equivalents). The mixture was heated under reflux under argon for 2 days. Methanol (20 mL) was carefully added, followed by water until the solution became cloudy. After cooling, the precipitate was collected by vacuum filtration and thoroughly washed with 1:1 water:methanol to obtain the title compound (6.20 g, 99%) as a green powder. δ H (CDCl3,400MHz)1.29(9H,s),1.45(9H,s),6.96(1H,d,J=8.9Hz),7.30(2H,app.d,J=8.5Hz),7.37(1H,dd,J=1.9 and 8.9Hz),7.40 (2H,app.d,J=8.5Hz),7.51(2H,app.d,J=8.5Hz),7.61(2H,app.d,J=8.5Hz),7.83(1H,dd,J=1.7 and 8.5Hz) and 8.69-8.76(3H,m);δ C (CDCl3, 100MHz) 31.16, 31.41, 34.70, 35.07, 119.07, 119.84, 122.01, 122.35, 124.59, 125.25, 125.95, 126.17, 126.84, 127.18, 127.22, 128.00, 128.41, 128.63, 128.88, 129.53, 129.89, 130.87, 135.61, 137.06, 151.67, 152.23 and 153.56.

[0136] 1,2-Bis[4-(tert-butyl)phenyl]-6,9-di(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole [ka] The samples were obtained from 6,9-dibromo-1,2-bis-[4-(tert-butyl)phenyl]-1H-phenanthro[9,10-d]imidazole (5.25 g, 8.20 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (3.53 g, 17.22 mmol, 2.1 equivalents), Pd(PPh3)4 (0.34 g, 0.287 mmol, 3.5 mol%), and K2CO3 (3.74 g, 17.22 mmol, 2.1 equivalents) in PhMe / EtOH (1:1, 120 mL) that had been degassed over 5 days. After extraction, the solvent was removed, and the residue was slurryed in DCM, passed through silica, and then through MeOH. The solvent was removed under vacuum, the residue was tritulated with Et2O, the resulting solid was collected by vacuum filtration, and air-dried to obtain the title compound (4.28 g, 82%) as a dark powder. δ H (CDCl3,400MHz)1.31(9H,s),1.48(9H,s),7.27(1H,d,J=8.5Hz),7.32(2H,d,J=8.5Hz),7.47(2H,d,J=8.4Hz),7.55-7.58(3H,m), 7.64-7.67(4H,m),7.75(2H,d,J=6Hz),8.01(1H,dd,J=1.2 and 8.3Hz),8.72(2H,d,J=6Hz),7.76(2H,d,J=6Hz),8.95-9.03(3H,m);δ C (CDCl3, 100MHz) 31.18, 31.45, 34.73, 35.11, 121.74, 121.78, 121.81, 122.02, 122.48, 123.70, 123.95, 125.29, 125.33, 126.32, 127.20, 127.36, 127.92, 128.39, 128.50, 128.57, 128.92, 129.28, 134.30, 135.29, 135.80, 137.70, 148.25, 148.84, 150.41, 150.42, 151.97, 152.27 and 153.55

[0137] Compound 15: 4,4'-([1,2-bis(4-(tert-butyl)phenyl]-3-methyl-1H-phenanthr[9,10-d]imidazole-3-ium-6,9-diyl)bis(1-methylpyridine-1-ium)tris(tetrafluoroborate) [ka] A mixture of 1,2-bis[4-(tert-butyl)phenyl]-6,9-di(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole (1.27 g, 2.0 mmol) and MeOTs (3.36 g, 18 mmol, 9.0 equivalents) was heated to 180°C with stirring under an argon atmosphere for 8 hours, cooled, tritulate with Et2O, and the solid was recovered by vacuum filtration to obtain a gray powder (2.75 g). A mixture of the crude product (1.17 g) and MeOTs (3.6 g) was heated to 180°C with stirring under argon for 32 hours, cooled, tritulate with Et2O, and the solid was recovered by vacuum filtration. The title compound (0.71 g, 36%) was obtained as a green powder by adding a filtered solid solution in a 1:1 MeOH:water solution to a 25 mL solution of NaBF4 (2.64 g, 24 mmol, 12.0 equivalents) in water while stirring. δ H (DMSO-d6,400MHz)1.28(9H,s),1.35(9H,s),4.39(3H,s),4.45(6H,bs),7.19(1H,d,J=8.8Hz),7.59-7.77(9H,m),8.26(1H,dd,J=1.5 and 8.9Hz),8. 65(1H,dd,J=1.5 and 8.9Hz),8.85(2H,app.d,J=7Hz),8.95(2H,app.d,J=6.7Hz),9.10-9.22(5H,m),9.88(1H,d,J=1.5Hz) and 9.93(1H,d,J=1.6Hz).δ F (DMSO-d6,376MHz)-148.26 and -148.21;δ C(DMSO-d6,100MHz)31.17,31.39,35.40,38.42,47.76,47.83,118.83,122.65 ,122.76,123.48,124.70,125.48,125.64,125.78,126.23,126.36,127.19,12 7.65, 127.90, 128.27, 128.42, 128.53, 130.25, 130.36, 131.57, 132.61, 133.41, 133.51, 138.02, 146.12, 146.25, 151.71, 153.58, 153.72, 155.16, and 155.90.

[0138] Example 16 5,10-Dibromo-1,2-bis[4-(tert-butyl)phenyl]-1H-phenanthro[9,10-d]imidazole [ka] Acetic acid (100 mL) was added to a stirred mixture of 4-tert-butylaniline (2.20 g, 14.6 mmol, 2.35 mL, 1.5 equivalents) and 4-tert-butylbenzaldehyde (1.58 g, 9.75 mmol, 1.53 mL). Then, 2,7-dibromophenanthrene-9,10-dione (3.58 g, 9.75 mmol) and ammonium acetate (9.38 g, 122 mmol, 12.5 equivalents) were added, and the mixture was heated under reflux under argon for 2 days. Methanol (20 mL) was carefully added, followed by water until the solution became cloudy. After cooling, the precipitate was collected by vacuum filtration and washed with 1:1 water:methanol to obtain a brown powder. The crude material was purified by column chromatography (neat DCM) to obtain the title compound (2.74 g, 44%) as an off-white powder. δ H(CDCl3,400MHz)1.30(9H,s),1.47(9H,s),6.91(1H,d,J=1.9Hz),7.33(2H,d,J=8.5Hz),7.41(2H,d,J=8.3Hz),7.52(1H,dd,J=1.9 and 8.7Hz ),7.62(2H,d,J=8.5Hz),7.66(2H,d,J=8.3Hz),7.69(1H,dd,J=2 and 9Hz),8.42(1H,d,J=8.7Hz),8.47(1H,d,J=9Hz) and 9.00(1H,d,J=2Hz);δ C (CDCl3, 100MHz) 31.17, 31.43, 34.73, 35.12, 120.83, 122.00, 123.76, 124.26, 124.76, 125.36, 125.41, 125.35, 127.05, 127.16, 127.22, 127.34, 127.76, 127.92, 128.38, 128.58, 128.79, 128.84, 135.41, 137.02, 151.40, 152.31, and 153.90.

[0139] 1,2-Bis[4-(tert-butyl)phenyl]-5,10-di(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole [ka] This was obtained from 5,10-dibromo-1,2-bis[4-(tert-butyl)phenyl]-1H-phenanthro[9,10-d]imidazole (2.63 g, 4.10 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.77 g, 8.61 mmol, 2.1 equivalents), Pd(PPh3)4 (0.17 g, 0.14 mmol, 3.5 mol%), and K2CO3 (1.87 g, 8.61 mmol, 2.1 equivalents) in degassed PhMe / EtOH (1:1, 80 mL) over 5 days. After extraction and subsequent solvent removal, the solid was crystallized from thermal PhMe to obtain the title compound (1.33 g, 51%) as a green powder. δ H(CDCl3,400MHz)1.31(9H,s),1.49(9H,s),7.22(2H,dd,J=1.5,4.6Hz),7.35(2H,app. d,J=8.5Hz),7.50-7.56(3H,m),7.60(2H,app.d,J=8.5Hz),7.69(2H,app.d,J=8.8.5Hz ),7.80-7.86(3H,m),7.95(1H,dd,J=2,8.6Hz),8.57(2H,dd,J=1.4,4.6Hz),8.76(2H,d d,J=1.4,4.6Hz),8.81(1H,d,J=8.8Hz),8.86(1H,d,J=8.8Hz),9.21(1H,d,J=1.9Hz);δ C (CDCl3, 100MHz) 31.17, 31.51, 34.74, 35.13, 119.32, 121.08, 121.22, 121.94, 123.00, 123.78, 124.08, 124.33, 125.17, 125.38, 127.27, 127.32, 128.00, 128.10, 128.24, 128.60, 128.94, 129.05, 135.25, 135.98, 136.95, 137.81, 147.45, 147.93, 150.27, 150.38, 151.60, 152.30, and 153.66.

[0140] Compound 16: 4,4'-([1,2-bis(4-(tert-butyl)phenyl]-3-methyl-1H-phenanthr[9,10-d]imidazole-3-ium-5,10-diyl)bis(1-methylpyridine-1-ium)tris(tetrafluoroborate) [ka] A mixture of 1,2-bis[4-(tert-butyl)phenyl]-5,10-di(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole (0.50 g, 0.79 mmol) and MeOTs (2.21 g, 11.9 mmol, 15 equivalents) was heated to 180°C under argon with stirring for 24 hours, cooled, tritulate with Et2O, and the solid was recovered by vacuum filtration. The filtrate of the solid in a 4:1MeOH:H2O solution was slowly added to a 15 mL solution of NaBF4 (0.78 g, 7.11 mmol, 9.0 equivalents) in stirred water and stirred for 30 minutes. The precipitate was collected by vacuum filtration and washed with water to obtain the title compound as a green powder (0.65 g, 86%). δ H (DMSO-d6,400MHz)1.27(9H,s),1.32(9H,s),4.35(3H,s),4.43(3H,s),4.57(3H,s), 7.56(1H,d,J=1.7Hz),7.63(2H,d,J=8.5Hz),8.69-7.82(6H,m),7.98(2H,d,J=6.8Hz) ,8.44(1H,dd,J=1.7 and 8.8Hz),8.60(1H,dd,J=1.3 and 8.8Hz),8.88(2H,d,J=6.8Hz),8. 96(2H,d,J=6.8Hz),9.17(2H,d,J=6.8Hz),9.28(1H,d,J=1.2Hz),9.47-9.57(2H,m);δ F (DMSO-d6, 376MHz) -148.25 and -148.2; δ C (DMSO-d6,100MHz)31.16,31.52,35.40,35.41,38.06,47.83,47.89,118.85, 121.13,121.70,122.46,123.15,124.81,125.76,125.90,126.38,126.92,127 .30, 127.65, 127.80, 127.87, 127.95, 128.38, 128.67, 131.03, 131.32, 131.61, 132.63, 134.18, 134.99, 146.26, 151.19, 153.50, 153.72, 155.16, and 155.89.

[0141] Example 17 6,9-Dibromo-1-[4-(tert-butyl)phenyl]-2-(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole [ka] To a stirred mixture of 4-pyridinecarboxaldehyde (1.04 g, 9.75 mmol, 0.91 mL) and 4-tert-butylaniline (2.20 g, 14.6 mmol, 2.35 mL, 1.5 equivalents), acetic acid (100 mL) was added, followed by 3,6-dibromophenanthrene-9,10-dione (3.58 g, 9.75 mmol) and ammonium acetate (9.38 g, 122 mmol, 12.5 equivalents). The mixture was heated under reflux under argon for 3 days. Methanol (20 mL) was carefully added, followed by water until the solution became cloudy. After cooling, the precipitate was collected by vacuum filtration, washed with 1 M K2CO3 solution, and air-dried to obtain the title compound (4.76 g, 83%) as a green powder. δ H (CDCl3,400MHz)1.47(9H,s),6.99(1H,d,J=8.9Hz),7.37-7.56(5H,m),7.66(2H,d, δ C (CDCl3, 100MHz) 154.42, 149.94, 148.27, 137.89, 137.36, 134.98, 131.13, 130.17, 129.05, 128.82, 128.24, 128.10, 127.59, 126.99, 126.06, 125.31, 124.51, 122.74, 122.47, 121.71, 120.39, 119.91, 35.19, and 31.40.

[0142] 1-[4-(tert-butyl)phenyl]-2,6,9-tri(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole [ka] The extract was obtained from 6,9-dibromo-1-(4-(tert-butyl)phenyl)-2-(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole (2.93 g, 5.00 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (2.15 g, 10.5 mmol, 2.1 equivalents), Pd(PPh3)4 (0.20 g, 0.18 mmol, 3.5 mol%), and K2CO3 (1.45 g, 10.5 mmol, 2.1 equivalents) in degassed PhMe / EtOH (1:1, 120 mL) over 6 days. After extraction and subsequent solvent removal, the residue was tritulated with water (250 mL) and then with Et2 (50 mL). The obtained solid was dissolved in a 10:1 PhMe:EtOH solution, cooled to -20°C overnight, and then concentrated under vacuum. The resulting precipitate was collected by vacuum filtration and washed with Et2O to obtain the title compound (1.50 g, 52%) as a brown powder. δ H (CDCl3,400MHz)1.50(9H,s),7.31(1H,d,J=8.7Hz),7.48-7.51(4H,m),7.56-7.77(7H,m),8.04(1H, dd,J=1.2 and 8.4Hz),8.56(2H,d,J=6.1Hz),8.73(2H,d,6Hz),8.76(2H,d,J=6Hz),8.94-9.05(3H,m);δ C (CDCl3, 100MHz) 31.43, 35.22, 121.81, 121.85, 122.01, 122.03, 122.60, 122.82, 123.38, 123.91, 125.62, 126.62, 127.61, 127.67, 128.19, 128.64, 129.29, 129.82, 135.12, 135.90, 137.63, 137.92, 148.05, 148.61, 149.95, 150.44, 150.47 and 154.42.

[0143] Compound 17: 4,4',4''-{[1-(4-(tert-butyl)phenyl]-3-methyl-1H-phenanthr[9,10-d]imidazole-3-ium-2,6,9-triyl}tris(1-methylpyridine-1-ium)tetrakis(tetrafluoroborate) [ka] A mixture of 1-[4-(tert-butyl)phenyl]-2,6,9-tri(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole (1.17 g, 2.0 mmol) and MeOTs (2.60 g, 14 mmol, 7.0 equivalents) was heated to 180°C under argon with stirring for 16 hours, cooled, tritulate with Et2O, and the solid was recovered by vacuum filtration. This solid was tritulated with a small amount of Et2O using a mortar and pestle, tritulated with Et2O, and air-driven to obtain a greenish-yellow powder. A mixture of the powder (1.55 g) and MeOTs (1.0 g, 5.4 mmol) was heated to 180°C under argon with stirring for 16 hours, cooled, tritulate with Et2O, and the solid was recovered by vacuum filtration. The title compound was obtained as a green powder (0.71 g, 36%) by dropping a filtration solution of the solid in hot MeOH:water (1:1) into a 25 mL solution of stirred water containing NaBF4 (2.64 g, 24.0 mmol, 12.0 equivalents), stirring for 30 minutes, and collecting the precipitate by vacuum filtration. δ H (DMSO-d6,400MHz)1.38(9H,s),4.39(3H,s),4.43(3H,s),4.45(3H,s),4.51(3H ,s),7.02(1H,d,J=8.8Hz),8.26(1H,dd,J=1.8 and 8.8Hz),8.50(2H,d,J=6.8Hz), 8.65(1H,dd,J=1.8 and 8.8Hz),8.84(2H,d,J=7.1Hz),8.95(2H,d,J=7Hz),9.12-9 .22(5H,m),9.27(2H,d,J=7Hz),9.87(1H,d,J=1.8Hz) and 9.93(1H,d,J=1.8Hz);δ F (DMSO-d6,376MHz)-148.27,-148.22;δ C(DMSO-d6, 400MHz) 31.41, 35.53, 38.62, 47.81, 47.88, 49.35, 122.24, 122.59, 122.95, 124.97, 125.58, 125.77, 126.37, 127.91, 128.22, 128.36, 128.55, 128.75, 130.62, 130.71, 131.28, 134.02, 134.15, 137.00, 145.64, 146.16, 146.28, 147.59, 153.41, 153.58 and 156.09.

[0144] Example 18 6,9-Dibromo-1-[4-(tert-butyl)phenyl]-2-(pyridine-4-yl)-1H-phenanthro[9,10-d]imidazole [ka] Acetic acid (100 mL) was added to a stirred mixture of 4-tert-butylaniline (2.20 g, 14.6 mmol, 2.35 mL, 1.5 equivalents) and 4-bromobenzaldehyde (1.80 g, 9.75 mmol), followed by the addition of 3,6-dibromophenanthrene-9,10-dione (3.58 g, 9.75 mmol) and ammonium acetate (9.38 g, 122 mmol, 12.5 equivalents). The mixture was heated under reflux argon for 2 days. Methanol (20 mL) was carefully added, followed by water until the solution became cloudy. After cooling, the precipitate was collected by vacuum filtration and washed with 1:1 water:methanol to obtain the title compound (6.10 g, 94%) as a green powder. δ H (CDCl3,400MHz)1.45(9H,s),6.97(1H,d,J=8.9Hz),7.34-7.44(7H,m),7.61(2H,d,J=8.4Hz),7.82(1H,dd,J=1.5 and 8.5Hz) and 8.64-8.74(3H,m);δ C(CDCl3, 100MHz) 31.40, 35.12, 119.40, 120.05, 121.83, 122.34, 123.61, 124.48, 126.00, 126.02, 126.90, 127.37, 128.18, 128.25, 128.68, 129.12, 129.66, 130.01, 130.67, 130.96, 131.49, 135.25, 137.11, 150.33 and 153.93.

[0145] 1-[4-(tert-butyl)phenyl]-6,9-di(pyridine-4-yl)-2-[4-(pyridine-4-yl)phenyl]-1H-phenanthro[9,10-d]imidazole [ka] The extract was obtained from 6,9-dibromo-1-[4-(tert-butyl)phenyl]-2-(4-bromophenyl)-1H-phenanthro[9,10-d]imidazole (5.44 g, 8.20 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (5.30 g, 25.8 mmol, 3.15 equivalents), Pd(PPh3)4 (0.34 g, 0.38 mmol, 3.5 mol%), and K2CO3 (5.61 g, 25.8 mmol, 3.15 equivalents) in PhMe / EtOH (1:1, 120 mL) that had been degassed over 7 days. After extraction and subsequent solvent removal, the residue was dissolved in hot 1:1 DCM:isopropanol, cooled overnight to -20°C, and then concentrated under vacuum. The resulting precipitate was collected by vacuum filtration and washed with Et2O to obtain the title compound (3.73 g, 59%) as a green powder. δ H (CDCl3,400MHz)1.49(9H,s),7.32(1H,d,J=8.6Hz),7.48-7.53(4H,m),7.57-7.62(3H,m),7.64-7.71(4H,m),7.73-7.79(4H,m),8. 06(1H,dd,J=1.4,8.3Hz),8.67(2H,dd,J=1.5,4.6Hz),8.73(2H,dd,J=1.5,4.6Hz),8.77(2H,dd,J=1.5,4.6Hz),8.98-9.07(3H,m);δ C(CDCl3, 100MHz) 31.45, 35.17, 121.46, 121.81, 121.91, 122.05, 122.58, 123.57, 123.93, 125.50, 126.50, 126.84, 127.40, 127.81, 128.23, 128.42, 128.53, 128.87, 129.53, 129.90, 130.98, 134.71, 135.58, 135.62, 137.86, 138.44, 147.30, 148.18, 148.77, 150.38, 150.44, 150.92, and 153.92.

[0146] Compound 18: 4,4'-{1-[4-(tert-butyl)phenyl]-3-methyl-2-(4-(1-methylpyridine-1-ium-4-yl)phenyl)-1H-phenantro[9,10-d]imidazole-3-ium-6,9-diyl}bis(1-methylpyridine-1-ium)tetrakis(tetrafluoroborate) [ka] 1-[4-(tert-butyl)phenyl]-6,9-di(pyridine-4-yl)-2-[4-(pyridine-4-yl)phenyl]-1H-phenanthro[9,10-d]imidazole (3.29 g, 5.0 mmol) and MeOTs (5.59 g, 30 mmol, 6.0 equivalents) were heated to 180°C under argon with stirring for 16 hours, cooled, triturated with Et2O, and the solid was collected by vacuum filtration. This solid was triturated with a small amount of Et2O using a mortar and pestle, then triturated with Et2O and air-driven to obtain a green powder. A mixture of the powder (4.91 g) and MeOTs (4.00 g, 21.5 mmol) was heated to 180°C under argon with stirring for 16 hours, cooled, triturated with Et2O, and the solid was recovered by vacuum filtration. The filtered solid solution in hot 1:1:MeOH water was added dropwise to a 65 mL solution of stirred water containing NaBF4 (6.59 g, 50 mmol, 12.0 equivalents), stirred for 30 minutes, and the precipitate was collected by vacuum filtration to obtain the title compound (4.17 g, 78%) as a khaki green powder. δ H(DMSO-d6,400MHz)1.35(9H,s),4.36(3H,s),4.39(3H,s),4.44(3H,s),4.48(3H,s),7.09(1H,d, J=8.8Hz),7.75(2H,d,8.6Hz),7.80(2H,d,J=8.6Hz),8.08(2H,d,J=8.4Hz),8.25(1H,dd,J=1.7,8 .9Hz),8.32(2H,d,J=8.5Hz),8.56(2H,d,J=6.9Hz),8.65(1H,dd,J=1.7,8.8Hz),8.85(2H,d,J=7 .1Hz), 8.95(2H,d,J=7.1,Ar-H),9.05-9.27(7H,m),9.88(1H,d,J=1.7Hz) and 9.95(1H,d,J=1.7);δ F (DMSO-d6, 376MHz) -148.25 and -148.20; δ C (DMSO-d6, 100MHz) 31.41, 35.45, 38.48, 47.78, 47.84, 122.63, 123.35, 124.77, 125.21, 125.51, 125.67, 125.78, 126.30, 127.41, 127.88, 128.17, 128.43, 128.60, 129.09, 130.35, 130.48, 132.33, 133.04, 133.57, 133.69, 137.67, 147.13, 146.27, 146.43, 150.26, 152.92, 153.51, 153.67 and 155.48.

[0147] 5. Benzoserenazoles Example 19 4-(benzoserenazole-2-yl)-1-hexylpyridine-1-ium iodide [ka] 2-(pyridine-4-yl)benzoserenazole (0.75 g, 2.89 mmol) and 1-iodohexane (1.23 mL, 8.67 mmol) were suspended in MeCN (40 mL) and stirred at 80°C for 16 hours. The reaction mixture was cooled to ambient temperature and the solvent was removed under reduced pressure. The resulting solid was triturated with acetone (20 mL), filtered, washed with acetone (20 mL), and dried under reduced pressure to obtain the target product as an orange powder. Yield: 1.10 g, 81%. δ H (CD3OD,300MHz)9.11(d,J=6.9Hz,2H),8.68(d,J=6.9Hz,2H),8.28(d,J=8.2Hz,1H),8.23(d,J=8.2Hz,1H),7.65(dd,J=7.3,1.2 Hz,1H),7.53(dd,J=7.3,1.2Hz,1H),4.67(t,J=7.6,2H),1.95(quint.,J=7.4Hz,2H),1.55-1.23(m,6H),0.94(t,J=6.8Hz,3H);δ C (DMSO-d6,100MHz)166.72,156.98,151.53,146.78,142.04,128.82,128.80,127.52,126.90,126.53,62.87,32.41,32.32,26.91,23.48,14.28.

[0148] Compound 19: 4-(benzoserenazole-2-yl)-1-hexylpyridine-1-iumtetrafluoroborate [ka] 4-(benzoserenazole-2-yl)-1-hexylpyridine-1-ium iodide (0.65 g, 1.38 mmol) was dissolved in hot MeOH (50 mL) and added dropwise to a stirred H2O (200 mL) solution of NaBF4 (5.0 g) via a cotton plug, forming a pale yellow precipitate. This solution was stirred for 30 minutes and then filtered under reduced pressure. The resulting solid was washed with water (30 mL) and dried under reduced pressure to obtain the target product as a pale yellow powder. Yield: 0.59 g, 76%. δ H(DMSO-d6,400MHz)9.20(d,J=6.7Hz,2H),8.74(d,J=6.7Hz,2H),8.39(d,J=8.0Hz,1H),8.28(d,J=8.0Hz,1H),7.66(dd,J=7.3,0. 9Hz,1H),7.55(dd,J=7.3,0.9Hz,1H),4.64(t,J=7.4,2H),1.95(quint.,J=6.5Hz,2H),1.43-1.20(m,6H),0.87(t,J=6.7Hz,3H);δ C (DMSO-d6,100MHz)166.57,154.99,148.64,145.71,140.40,127.61,127 .34,126.49,125.91,125.21,60.57,30.68,30.56,25.05,21.84,13.81;δ B (DMSO-d6,128MHz)-1.3;δ F (DMSO-d6,376MHz)-148.27(br.m,4F).

[0149] Example 20 4-(benzoserenazole-2-yl)-1-phenylpyridine-1-ium trifluoromethanesulfonate [ka] 2-(pyridinyl)benzoserenazole (1.00 g, 3.86 mmol), diphenyliodonium triflate (2.49 g, 5.79 mmol), and Cu(OAc)2·H2O (116 mg, 0.58 mmol) were dissolved in DMF (30 mL) under N2, and the reaction mixture was stirred at 100°C for 16 hours. The reaction mixture was cooled to room temperature, and the solvent was removed under reduced pressure. The resulting yellow solid was triturated with hot MeOH, filtered, and dried under reduced pressure to obtain the target product as a yellow powder. Yield: 1.70 g, 91%. δ H(DMSO-d6,400MHz)9.46(d,J=6.9Hz,2H),8.86(d,J=6.9Hz,2H),8.42(d,J=7.8Hz,1H),8.33(d,J=7.8H z,1H),8.00-7.90(m,2H),7.84-7.74(m,3H),7.69(dd,J=7.4,1.1Hz,1H),7.58(dd,J=7.4,1.1Hz,1H);δ C (DMSO-d6,100MHz)166.28,155.14,149.35,145.83,142.39,140.80,131. 40,130.24,127.75,127.55,126.60,126.14,124.97,124.68,120.65(d,J C-F =320.4Hz);δ F (DMSO-d6, 376MHz)-77.76(s,3F).

[0150] Compound 20: 4-(benzoserenazole-2-yl)-1-phenylpyridine-1-iumtetrafluoroborate [ka] 4-(benzoserenazole-2-yl)-1-phenylpyridine-1-ium trifluoromethanesulfonate (1.00 g, 2.06 mmol) was dissolved in hot MeOH (50 mL) and added dropwise to a stirred H2O (200 mL) solution of NaBF4 (5.0 g) via a cotton plug, forming a pale yellow precipitate. This solution was stirred for 30 minutes and then filtered under reduced pressure. The resulting solid was washed with water (30 mL) and dried under reduced pressure to obtain the target product as a yellow powder. Yield: 0.61 g, 70%. δ H (DMSO-d6,400MHz)9.45(d,J=6.9Hz,2H),8.55(d,J=6.9Hz,2H),8.41(d,J=7.8Hz,1H),7.32(d,J=7.8H z,1H),8.00-7.87(m,2H),7.83-7.72(m,3H),7.67(dd,J=7.4,1.1Hz,1H),7.57(dd,J=7.4,1.1Hz,1H);δ C(DMSO-d6,100MHz)166.30,155.16,149.36,145.84,142.40,140.82,131.43,130.27,127.77,127.57,126.61,126.16,124.99,124.69;δ B (DMSO-d6,128MHz)-1.3;δ F (DMSO-d6,376MHz)-148.21(br.m,4F).

[0151] Example 21 Compound 21: 4-(benzoserenazole-2-yl)-1-phenylpyridine-1-ium hexafluorophosphate [ka] 4-(benzoserenazole-2-yl)-1-phenylpyridine-1-ium trifluoromethanesulfonate (0.20 g, 0.47 mmol) was dissolved in hot MeOH (20 mL) and added dropwise to a stirred H2O (100 mL) solution of NH4PF6 (0.50 g) via a cotton plug, forming a yellow precipitate. This solution was stirred for 30 minutes and then filtered under reduced pressure. The resulting solid was washed with water (30 mL) and dried under reduced pressure to obtain the target product as a yellow powder. Yield: 0.13 g, 71%. δ H [(CD3)2CO,400MHz]9.52(d,J=6.3Hz,2H),8.98(d,J=6.3Hz,2H),8.38(d,J=8.5Hz,1H),8.36(d,J =8.5Hz,1H),8.13-7.95(m,2H),7.92-7.78(m,3H),7.73(t,J=7.6Hz,1H),7.61(t,J=7.6Hz,1H);δ C [(CD3)2CO,100MHz]166.22,156.65,151.54,146.67,143.78,141.91,132.64,131.45,128.74,128.71,127.39,126.99,126.34,125.43;δ P [(CD3)2CO,162MHz]-144.27(sept.,J=707.8Hz,1P);δ F[(CD3)2CO,376MHz]-72.51(d,J=707.8Hz,6F).

[0152] 6. Benzoxazoles and Benzoisoxazoles Example 22 2-(pyridine-4-yl)-2,3-dihydrobenzoxazole [ka] A solution of 2-aminophenol (8.00 g, 73.4 mmol) and pyridine-4-carboxyaldehyde (7.85 g, 73.4 mmol) in EtOH (350 mL) was stirred under air for 5 days. The solvent was concentrated under reduced pressure, the resulting solid was filtered, washed with EtOH (20 mL), and air-dried to obtain the title compound (13.36 g, 92%) as an orange powder. δ H (CDCl3,400MHz)6.93(1H,app.t,J=7.7Hz),7.04(1H,app.d,J=8.1Hz),7.22-7.31(2 H,m),7.35(1H,app.d,J=8.0Hz),7.76(2H,bd,J=4.5Hz),8.69(1H,s) and 8.78(2H,bs).

[0153] 2-(pyridine-4-yl)benzoxazole [ka] 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (1.15 g, 5 mmol) was added all at once to a solution of 2-(pyridine-4-yl)-2,3-dihydrobenzoxazole (1.00 g, 5 mmol) in DCM (50 mL) with stirring. Stirring was continued for 1 hour, and Et3N (5 mL) was added. The resulting solution was filtered through silica using DCM (100-0% in siRNA) as the eluent. The first band was collected to obtain the title compound (0.43 g, 43%) as a pale yellow powder. The second band was collected to obtain the unreacted starting material (0.28 g, 28%). δ H(CDCl3, 400MHz) 7.39-7.47 (2H,m), 7.61-7.66 (1H,m), 7.81-7.85 (1H,m), 8.10 (2H,dd,J=1.6 and 4.6Hz) and 8.83 (2H,dd,J=1.6 and 4.6Hz).

[0154] 4-(benzoxazole-2-yl)-1-hexylpyridine-1-ium iodide [ka] A solution of 2-(pyridine-4-yl)benzoxazole (1.00 g, 5.1 mmol) and 1-iodohexane (3.24 g, 15.3 mmol) in MeCN (30 mL) was heated under reflux with stirring in the dark under N2. After 16 hours, the resulting mixture was cooled and diluted with Et2O (50 mL). The precipitate was filtered, washed with Et2O (3 × 10 mL), and air-dried to obtain the title compound (2.06 g, 99%) as a yellow powder.

[0155] Compound 22: 4-(benzoxazole-2-yl)-1-hexylpyridine-1-iumtetrafluoroborate [ka] A solution of 4-(benzoxazole-2-yl)-1-hexylpyridine-1-ium iodide (2.01 g, 4.9 mmol) in warm MeOH / water (50 mL, 1:1) was added dropwise to a solution of NaBF4 (5.42 g, 40 mmol) in water (100 mL) with stirring. Stirring was continued for 0.5 hours, the resulting precipitate was filtered, washed with water (3 × 10 mL), and air-dried to obtain the title compound (1.77 g, 98%) as a colorless powder. δ H(CD3OD,400MHz)0.89-0.97(3H,bt,J=5.7Hz),1.30-1.51(6H,m),2.00-2.14(2H,m),4.69(2H,bt,J=7.4Hz),7. 50-7.65(2H,bm),7.83(1H,bd,J=8.2Hz),8.93(1H,bd,J=8Hz),8.78(2H,bd,J=5.5Hz) and 9.16(2H,bd,J=5.5Hz).

[0156] Example 23 4-(benzoxazole-2-yl)-1-phenylpyridine-1-ium triflat [ka] A mixture of 2-(pyridine-4-yl)benzoxazole (1 g, 5.1 mmol), diphenyliodonium triflate (3.29 g, 7.6 mmol), and Cu(OAc)2·H2O (100 mg, 10 mol%) in dry DMF (50 mL) was heated at 100°C for 16 hours, cooled, and the solvent was removed under reduced pressure. The residue was tritulated with Et2O (50 mL), washed with Et2O (3 × 10 mL), and air-dried. The resulting solid was tritulated with hot MeOH (20 mL), cooled, filtered, and air-dried to obtain the title compound (1.86 g, 86%) as a colorless powder. δ H (CD3OD,400MHz)7.54-7.70(2H,bm),7.76-8.00(7H,bm),8.93(2H,bd,J=5.9Hz) and 9.42(2H,bd,J=5.9Hz).

[0157] Compound 23: 4-(benzoxazol-2-yl)-1-phenylpyridine-1-iumtetrafluoroborate [ka] A solution of 4-(benzoxazole-2-yl)-1-phenylpyridine-1-ium triflate (0.25 g, 0.59 mmol) in warm MeOH (10 mL) was added dropwise to a solution of NaBF4 (0.65 g, 5.9 mmol) in water (30 mL) with stirring. The resulting precipitate was filtered, washed with water (2 × 3 mL), dissolved in warm MeOH (10 mL), and added dropwise to a solution of NaBF4 (0.65 g, 5.9 mmol) in water (30 mL), and stirred for 0.5 hours. The resulting precipitate was filtered, washed with water (2 × 3 mL), and air-dried to obtain the title compound (0.20 g, 95%) as a pale yellow powder. δ H (DMSO-d6,400MHz)7.56-7.62(1H,m),7.64-7.70(1H,m),7.74-7.82(3H,m),7.91-8 .01(3H,m), 8.05(1H,d,J=7.9Hz), 8.87(2H,bd,J=6.8Hz) and 9.53(2H,bd,J=6.8Hz).

[0158] Example 24 4-(2-methoxybenzoyl)pyridine [ka] A freshly prepared solution of 2-methoxyphenylmagnesium bromide (40 mL, approximately 1.38 M, 55.4 mmol) was added to a stirred solution of 4-cyanopyridine (2.78 g, 26.7 mmol) in dry THF (20 mL) cooled to 0°C under N2. After the addition was complete, the reaction mixture was stirred and heated at 50°C under N2 for 16 hours. The solution was then cooled to 0°C and H2O (20 mL) was slowly added. The reaction mixture was evaporated to dryness under reduced pressure, then 2 M HCl (100 mL) was added, and the solution was heated at 80°C for 8 hours. The reaction mixture was then cooled to room temperature and the solution was washed with HCl (2 × 100 mL). The aqueous phase was based with NaOH (5 M) and extracted with DCM (3 × 100 mL). The organic layers were combined, dried (Na2SO4), filtered, and the solvent was removed under reduced pressure. The obtained residue was chromatographed using silica gel [eluent ratio was gradually changed from 1:9 to 1:1 SiO:petroleum ether]. The title compound was obtained as a yellow oily liquid by removing the solvent from the resulting column fraction under reduced pressure. Yield: 4.60 g, 82%. δ H (CDCl3,400MHz)8.75(2H,dd,J=4.4,1.6Hz),7.57-7.51(3H,m),7.46(1H,dd,J= 7.6,1.8Hz), 7.07(1H,td,J=7.55,0.9Hz),6.99(1H,d,J=8.3Hz) and 3.68(3H,s);δ C (CDCl3, 100MHz) 195.6, 158.0, 150.5, 144.8, 133.5, 130.5, 127.3, 122.4, 121.0, 111.7 and 55.6.

[0159] 3-(pyridine-4-yl)-1,2-benzisoxazole [ka] 4-(2-methoxybenzoyl)pyridine (3.60 g, 16.8 mmol) was dissolved in dry DCM (100 mL) and cooled to 0°C under N2. BBr3 (8.42 g, 3.24 mL, 33.6 mmol) was added dropwise, and the reaction mixture was stirred for 16 hours. The reaction mixture was added to ice, neutralized with NaHCO3, and stirred for 1 hour. Next, the reaction mixture was extracted with DCM (2 × 200 mL), the organic layers were combined, dried (Na2SO4), filtered, and the solvent was removed under reduced pressure. The resulting residue was chromatographed using silica gel [eluent = gradually changed from 1:9 to 4:6 siRNA:petroleum ether]. By removing the solvent from the resulting column fraction under reduced pressure, 4-(2-hydroxybenzoyl)pyridine (2.60 g) containing impurities was obtained as a yellow solid. This was used in subsequent reactions without further purification. 4-(2-hydroxybenzoyl)pyridine (2.60 g) containing impurities was dissolved in 7N ammonia in methanol (30 mL) and stirred at room temperature for 48 hours to obtain an orange solution. Next, the reaction mixture was evaporated to dryness under reduced pressure and redissolved in dry THF (40 mL) under N2. Then, N-chlorosuccinimide (2.60 g, 19.5 mmol) and K2CO3 (3.60 g, 138 mmol) were added to the reaction mixture and stirred at room temperature under N2 for 16 hours. Subsequently, the reaction mixture was diluted with diethyl ether (100 mL) and quenched with water (100 mL). The organic layer was separated, and the aqueous layer was extracted with diethyl ether (2 × 100 mL). The organic layers were combined, dried (Na2SO4), filtered, and the solvent was removed under reduced pressure. The resulting residue was chromatographed using silica gel [eluent ratio was gradually changed from 1:9 to 3:7 siRNA:petroleum ether]. The solvent in the obtained column fraction was removed under reduced pressure to obtain a pale yellow solid. This solid was triturated with pentane and dried under reduced pressure to obtain the title compound as an off-white solid. Yield: 1.2 g, 36%. δ H(CDCl3,400MHz)8.84(2H,dd,J=4.5,1.5Hz),7.95(1H,dt,J=8.0,0.9Hz),7.89(2H,dd,J=4.4,1.6Hz )7.70(1H,dt,J=8.4,0.8Hz),7.67(1H,ddd,J=8.5,7.0,1.0Hz) and 7.44(1H,ddd,J=8.5,7.0,1.0Hz);δ C (CDCl3,100MHz)164.3,155.4,150.9,136.7,130.4,124.6,122.3,1217,119.9,110.6.

[0160] Compound 24: 4-(1,2-benzisoxazole-3-yl)-1-phenylpyridine-1-iumhexafluorophosphate [ka] Dissolve 3-(pyridine-4-yl)-1,2-benzisoxazole (1.00 g, 5.1 mmol), diphenyliodonium trifluoromethanesulfonate (3.29 g, 7.64 mmol), and Cu(OAc)2·H2O (0.1 g, 0.51 mmol) in DMF (40 mL) under N2 conditions to prepare the reaction mixture 100 oThe mixture was stirred for 16 hours. The reaction mixture was cooled to room temperature, and the solvent was removed under reduced pressure. The resulting pale green solid was tritulated with diethyl ether (3 × 50 mL), filtered, and dried under reduced pressure. The resulting water-absorbing pale green solid was dissolved in hot MeOH:H2O (approximately 2:1, 150 mL) and added dropwise through a cotton plug to a stirred solution of NH4PF6 (17.5.0 g) in H2O (350 mL), forming a pale yellow precipitate. The suspension was stirred for 30 minutes and then filtered under reduced pressure. The resulting solid was washed with water (50 mL) and dried under reduced pressure to obtain a pale green powder. This solid was then dissolved in hot acetone:H2O (approximately 2:1, 200 mL), and added dropwise through a cotton plug to the filtrate (which had decreased by approximately 20% under vacuum) to obtain a pale green precipitate. Next, the resulting suspension was filtered under reduced pressure, the solid was washed with water (50 mL), and dried under reduced pressure to obtain a pale green powder. The green powder was tritulated with MeOH (50 mL), filtered, and dried under reduced pressure to obtain the title compound as a colorless powder. Yield: 1.17 g, 55%. δ H (DMSO-d6,400MHz)9.60(2H,d,J=7.0Hz),8.96(2H,d,J=6.9Hz),8.43(1H,d,J=8.1Hz),8.09(1H,d,J=8.6Hz) 8.05-7.98(2H,m),7.93(1H,ddd,J=8.5,7.1,1.0Hz),7.89-7.79(3H,m) and 7.72(1H,ddd,J=8.5,7.3,0.5Hz);δ C (DMSO-d6, 100MHz) 164.1, 153.3, 146.0, 144.1, 142.5, 131.6, 131.5, 130.3, 126.2, 125.8, 124.8, 122.4, 118.6 and 110.7; δ F (DMSO-d6,376MHz)-170.13(6F,d,J=711.0Hz).

[0161] Evaluation of the redox potential and absorption spectrum of the compound of the present invention. Method for measuring oxidation-reduction potential The redox potential of a compound is measured by cyclic voltammetry using three electrodes. The following three electrodes are used: • One platinum fabrication electrode • One platinum auxiliary electrode or counter electrode A single platinum reference electrode immersed in a solution of 0.01 M AgNO3 + 0.1 M TBAP (tetrabutylammonium perchlorate) in acetonitrile.

[0162] The potential scan rate is fixed at 100 mV / s. E1 red This corresponds to the first reduction peak of the analyte. E2 red This corresponds to the second reduction peak of the analyte. E1 1 / 2 This corresponds to the redox potential of the oxidizing agent / reducing agent system, which is calculated as follows. E1 1 / 2 =(E1 red +E1 ox ) / 2 Here, E1 ox This corresponds to the first oxidation peak of the analyte compound. ΔE red E1 is calculated as follows: red and E2 red Corresponding to: ΔE red =│E2 red │-│E1 red │.

[0163] The displayed potential value is the initial reduction potential of the compound, relative to the standard hydrogen reference electrode (SHE).

[0164] The analytical solution contains 0.005 M of the analyte compound and 0.25 M of TBABF4 salt, with propylene carbonate as the solvent.

[0165] Method for measuring absorption spectra This solution is introduced into the quartz cell as follows.

[0166] This solution is introduced into a quartz cell, and at least one working electrode in the form of a platinum grid is placed on it. The analyte compound is then colored on this electrode. The time-domain absorption spectrum of the analyte compound is measured by ultraviolet-visible spectroscopy.

[0167] The results for each synthesized compound are shown in Table 1 below. E1 red This corresponds to the first reduction potential. The colors shown in Table 1 are the visual colors perceived by an emmetropic eye under daylight conditions. λ max Please note that the values ​​are only approximate indicators of the color of a particular compound. However, due to the broad range of absorption bands, the entire absorption spectrum must be considered to understand the final color of a compound.

[0168] For comparison, Table 2 shows the results obtained for three known compounds.

[0169] When compounds 2 (orange) and 6-7 (red) of the present invention are compared with the known compound COMP1 (green), it appears that substituting one phenylpyridinium group with one substituted benzimidazolium group or substituted benzothiazolium group reduces the maximum absorption wavelength in the visible range to 645 nm to 550 nm or less. In the activated state, these molecules are red or orange, not green.

[0170] Comparing compounds 1, 10, 16 (orange), 3, 4, 5 (purple), 8 (green), 9, 11 (yellow / green), and 13-14 (yellow) with the known compounds COMP2 (blue) and COMP3 (blue), it is thought that the presence of different groups such as imidazolium, benzimidazolium, and benzothiazolium, either individually or in more complex molecular structures, can shift the maximum absorption wavelength to lower wavelengths. These groups can be introduced between two alkylbipyridinium groups or can substitute for the central pyridinium group of terpyridinium. The molecules thus obtained are not blue, but yellow, orange, red, green, or purple.

[0171] As a result, it was found that COMP3, a known compound containing a phenyl group between two alkylbipyridinium groups, was also orange in color and had an activation potential of -1.21V. Except for compounds 11 and 14, the compounds of the present invention have activation potentials equal to or lower than those of COMP3.

[0172] [Table 6]

[0173] Table 7

[0174] Table 8

[0175] Table 9

[0176] Table 10

Claims

1. Equation (I): 【Chemistry 1】 (In the formula, A is N, ＋ N, N-R １ , ＋ N-R １ or CR １ And, B is C-R ２ , S, Se, O, N, N-R ２ or ＋ N-R ２ and is D is C-R ３ , N, S, O, Se, N-R ３ or ＋ N-R ３ And, E is C, N or ＋ N is, R １ H, C １ ~C １８ Alkyl, aryl, or Z, R ２ H, C １ ~C １８ Alkyl, aryl, Z, or aryl substituted with Z, R ３ is H or C １ ~C １８ Alkyl, aryl, or Z, R ４ H, C １ ~C １８ Alkyl, aryl, or Z, R ５ H, C １ ~C １８ Alkyl, aryl, or Z, R ６ H, C １ ~C １８ Alkyl, aryl, or Z, R ７ H, C １ ~C １８ Alkyl, aryl, or Z, R ７ and R ６ , and / or R ６ and R ５ , and / or R ５ and R ４ These can optionally be substituted by Z, and together form aromatic rings or heteroaromatic rings condensed on a 6-membered (complex) cyclic core (ring C6) to which they are bonded. Here, Z is 【Chemistry 2】 And, Y is C １ ~C １８ Alkyl, (hetero)aryl, or (hetero)arylalkyl, R ８ , R ９ , R １０ and R １１ H and C １ ~C １８ Selected independently of alkyl, R ８ and R ９ or R １０ and R １１ These can form aromatic rings condensed with the pyridium groups to which they are bonded. In the case of B = C - Z and A = ＋ In the case of N, R ８ or R １１ Together with A, it can form an aromatic or non-aromatic ring fused with the five-membered heterocycle (ring C5) to which A is bonded. n is chosen to balance the number of positive charges, X is the counterion, 【Transformation 3】 These are single or double bonds, However, the following three points apply: 1) Ring C5 is a 5-membered heteroring, and A, B, D, and two E are N, N-R １ , ＋ N-R １ N-R ２ , ＋ N-R ２ N-R ３ , ＋ N-R ３ , to be selected independently from S, Se and O, 2) Rings C5 and C6 form a conjugated system, and 3) R １ , R ２ , R ３ , R ４ , R ５ , R ６ or R ７ At least one of them is Z, or at least R ７ and R ６ together form an aromatic ring substituted by Z, or at least R ５ and R ６ together form an aromatic ring substituted by Z, or at least R ５ and R ４ This involves forming an aromatic ring substituted by Z. (Conditional conditions apply) An electrochromic compound represented by [the specified symbol].

2. Formula (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X): 【Chemistry 4】 【Transformation 5】 【Transformation 6】 【Transformation 7】 (In the formula, A, B, D, E, R １ , R ２ , R ３ , R ４ , R ５ , R ６ , R ７ , R ８ , R ９ , R １０ and R １１ If present, it is as defined in claim 1, Z, Y, n, and X are also as defined in claim 1. A compound of formula (I) according to claim 1, represented by [the given formula].

3. A is N, ＋ N, N-R １ or ＋ N-R １ and / or B is N, N-R ２ or ＋ N-R ２ and / or D is N, N-R ３ or ＋ N-R ３ The compound of formula (I) according to claim 1 or 2, wherein

4. E is N or ＋ A compound of formula (I) according to any one of claims 1 to 3, wherein N is and / or D is S.

5. A is N, ＋ N, N-R １ or ＋ N-R １ And, D is N-R ３ , ＋ N-R ３ , S, Se or O, E is C, and R １ , R ３ , R ４ , R ５ , R ６ , R ７ , R ８ , R ９ , R １０ , R １１ A compound of formula (II) according to claim 2 or 3, wherein Z, Y, n, and X are as defined in claim 1.

6. A is N ＋ or ＋ N-R １ And, D is S, E is C, and R １ , R ４ , R ５ , R ６ , R ７ , R ８ , R ９ , R １０ , R １１ A compound of formula (II) according to claim 5, wherein Z, Y, n, and X are as defined in claim 1.

7. A is, ＋ N is, D is S, E is C, and R ８ Together with A, it forms an unsaturated or unsaturated 5 or 6-membered ring condensed with ring C5 to which A is bonded, and is of formula (XI), (XII), or (XIII) 【Transformation 8】 Represented by, and R ４ , R ５ , R ６ , R ７ , R ９ , R １０ , R １１ A compound of formula (II) according to claim 6, wherein Z, Y, n, and X are as defined in claim 1.

8. A is, ＋ N-R １ And, D is S, E is C, and R １ , R ４ , R ５ , R ６ , R ７ , R ８ , R ９ , R １０ , R １１ A compound of formula (II) according to claim 6, wherein Z, Y, n, and X are as defined in claim 1.

9. R ７ and R ６ , and / or R ６ and R ５ , and / or R ５ and R ４ These optionally substitute with Z, forming together aromatic or heteroaromatic rings condensed on the (complex) cyclic core (ring C6) to which they are bonded, and R １ , R ８ , R ９ , R １０ , R １１ A compound of formula (II) according to claim 8, wherein Z, Y, n, and X are as defined in claim 1.

10. R ８ and R ９ or R １０ and R １１ These form aromatic rings condensed to the pyridium groups to which they are bonded, and R １ , R ４ , R ５ , R ６ , R ７ A compound of formula (II) according to claim 8, wherein Z, Y, n, and X are as defined in claim 1. 【Request Item 11】 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 【Chemistry 12】 A compound of formula (I) according to claim 1, selected from the following.

12. An electrochromic composition comprising at least one compound according to any one of claims 1 to 11.

13. The electrochromic composition according to claim 12, further comprising a host medium, preferably a fluid, a liquid crystalline medium, or a gel.

14. An electrochromic device comprising a compound according to any one of claims 1 to 11 or an electrochromic composition according to claim 12 or 13.

15. The electrochromic device according to claim 14, wherein the optical article is selected from optical articles, preferably optical lenses or optical filters, windows, particularly aircraft windows, visors, mirrors, head-mounted devices and displays, more preferably from optical lenses, and most preferably from spectacle lenses.

Images